Ponatinib | AP24534 | 普纳替尼 (AP24534) | Bcr-Abl | VEGFR | PDGFR | TGF-beta/Smad

首页 / / / / Ponatinib

普纳替尼 /Ponatinib {[allProObj[0].p_purity_real_show]}

货号：A485520 同义名： 普纳替尼 (AP24534) / AP24534

Ponatinib (AP24534) 是一种口服活性的多靶点激酶抑制剂，对 Abl 的 IC50 为 0.37 nM，对 PDGFRα 为 1.1 nM，对 VEGFR2 为 1.5 nM，对 FGFR1 为 2.2 nM，对 Src 为 5.4 nM。

Ponatinib 化学结构
CAS号：943319-70-8

Ponatinib 3D分子结构
CAS号：943319-70-8

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Ponatinib 纯度/质量文件产品仅供科研

货号：A485520 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]; • JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]; • BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]; • J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]; • PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]; 更多 >

转化生长因子-β 亚型比较
Bcr-Abl 亚型比较
PDGFR 亚型比较
VEGFR 亚型比较

产品名称	ALK1 ↓ ↑	ALK2 ↓ ↑	ALK3 ↓ ↑	ALK4 ↓ ↑	ALK6 ↓ ↑	Smad3 ↓ ↑	TGF-β ↓ ↑	TGFβRI/ALK5 ↓ ↑	TGFβRII ↓ ↑	纯度
LDN193189	++++ ALK1, IC50: 0.8 nM	++++ ALK2, IC50: 0.8 nM	+++ ALK3, IC50: 5.3 nM		+++ ALK6, IC50: 16.7 nM					99%+
LDN-212854	++++ ALK1, IC50: 2.4 nM	++++ ALK2, IC50: 1.3 nM	+ ALK3, IC50: 85.8 nM	+ ALK4, IC50: 2133 nM				+ ALK5, IC50: 9276 nM		99%+
ML347	++ ALK1, IC50: 46 nM	++ ALK2, IC50: 32 nM								98%
K02288	++++ ALK1, IC50: 1.8 nM	++++ ALK2, IC50: 1.1 nM	++ ALK3, IC50: 34.4 nM		+++ ALK6, IC50: 6.4 nM					99%+
LDN-193189 dihydrochloride	++++ ALK1, IC50: 0.8 nM	++++ ALK2, IC50: 0.8 nM	+++ ALK3, IC50: 5.3 nM		+++ ALK6, IC50: 16.7 nM					99%
LDN-214117		++ ALK2, IC50: 24 nM								98%
DMH-1		+ ALK2, IC50: 107.9 nM								99%+
SB-505124				+ ALK4, IC50: 129 nM				++ ALK5, IC50: 47 nM		99%+
Vactosertib				+++ ALK4, IC50: 13 nM				+++ ALK5, IC50: 11 nM		99%+
Alantolactone						✔				98%
SIS3						✔				97%
Pirfenidone							✔			98%
Hesperetin							✔			97%
RepSox								++++ TGFβR1(ALK5), IC50: 4 nM		98%
GW788388								+++ ALK5, IC50: 18 nM		98%
LY364947								++ TGFβRI, IC50: 59 nM	+ TGFβRII, IC50: 0.4 μM	98%
SD-208								++ TGF-βRI (ALK5), IC50: 48 nM		98%
SB-525334								+++ TGFβR1(ALK5), IC50: 14.3 nM		99%+
LY2109761								++ TβRI, Ki: 38 nM	+ TβRII, Ki: 300 nM	99%+
Galunisertib								++ TβRI, IC50: 56 nM		98%
SB 431542								+ ALK5, IC50: 94 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	Abl ↓ ↑	Bcr-Abl ↓ ↑	其他靶点	纯度
NVP-BHG 712	+ c-Abl, IC50: 1.667 μM			99%+
KW-2449	+++ Abl (T315I), IC50: 4 nM Abl, IC50: 14 nM		FLT3	99%+
Ponatinib	++++ Abl, IC50: 0.37 nM			98%
AT9283				99%+
Imatinib Mesylate	+ v-Abl, IC50: 600 nM		c-Kit,PDGFR	99%
Danusertib	++ Abl, IC50: 25 nM		RET	99%+
Rebastinib	++++ u-Abl1 (T315I), IC50: 5 nM p-Abl1 (native), IC50: 0.75 nM		FLT3,Tie-2	99%+
PP121	++ Abl, IC50: 18 nM		VEGFR,PDGFR	99%+
GNF-7	+++ M351T, IC50: 133 nM E255V, IC50: 122 nM			99%+
Olverembatinib dimesylate	++++ Abl, IC50: 0.34 nM Abl (G250E), IC50: 0.35 nM			99%
Dasatinib monohydrate	++++ Abl , IC50: 0.6 nM		Src	98%
Dasatinib	++++ Abl, IC50: 0.6 nM		Src	98%
Bafetinib	+++ Abl, IC50: 5.8 nM			98+%
GNF-2		+ Bcr-Abl (K562 cell line), IC50: 273 nM Bcr-Abl (SUP-B15 cell line), IC50: 268 nM		98%+
Degrasyn		+ Bcr-Abl, IC50: 1.8 μM	DUB	98+%
GNF-5		++ Bcr-Abl, IC50: 220 nM		98%
Radotinib		++ BCR-ABL1, IC50: 34 nM		98+%
PD173955			Src	99%+
Nilotinib		++ Bcr-Abl, IC50: <30 nM		98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	PDGFR ↓ ↑	PDGFRα ↓ ↑	PDGFRβ ↓ ↑	其他靶点	纯度
Tyrphostin A9	+ PDGFR, IC50: 0.5 μM			EGFR	98%
Tyrphostin AG1296					99%+
Motesanib Diphosphate	++ PDGFR, IC50: 84 nM				98%
Pazopanib	++ PDGFR, IC50: 84 nM				99%
Imatinib	+ PDGFR, IC50: 100 nM			c-Kit	98%
Imatinib Mesylate	+ PDGFR, IC50: 100 nM			c-Kit	99%
Sennoside B	✔				99%+
PP121	++++ PDGFR, IC50: 2 nM			mTOR,VEGFR	99%+
Crenolanib		++++ PDGFRα, Kd: 2.1 nM	++++ PDGFRβ, Kd: 3.2 nM		99%+
Masitinib		+ PDGFRα, IC50: 540 nM	+ PDGFRβ, IC50: 800 nM		99%+
Ki8751		++ PDGFRα, IC50: 67 nM		c-Kit	98+%
Tivozanib		++ PDGFRα, IC50: 40 nM	++ PDGFRβ, IC50: 49 nM		99%+
Ponatinib		++++ PDGFRα, IC50: 1.1 nM			98%
Amuvatinib		++ PDGFRα (V561D), IC50: 40 nM			99%+
Axitinib		+++ PDGFRα, IC50: 5.0 nM	++++ PDGFRβ, IC50: 1.6 nM		98%
CP-673451		+++ PDGFRα, IC50: 10 nM	++++ PDGFRβ, IC50: 1 nM		99%+
Telatinib		+++ PDGFRα, IC50: 15 nM		c-Kit	99%+
Nintedanib		++ PDGFRα, IC50: 59 nM	++ PDGFRβ, IC50: 65 nM		99+%
Avapritinib		++++ PDGFRα (D842V), IC50: 0.5 nM			99%+
MK-2461			+++ PDGFRβ, IC50: 22 nM		98%+
Lactate			+++ PDGFRβ, IC50: 27 nM	c-Kit,FLT3	85%
Linifanib			++ PDGFRβ, IC50: 66 nM		99%+
AZD2932			+++ PDGFRβ, IC50: 4 nM	c-Kit	98%
Dovitinib			+++ PDGFRβ, IC50: 27 nM	c-Kit,FLT3	99%+
Sorafenib			++ mPDGFRβ, IC50: 57 nM PDGFRβ, IC50: 57 nM		99%
Sunitinib			++++ PDGFRβ , IC50: 2 nM	FLT3	98%
Orantinib			+++ PDGFRβ, Ki: 8 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	VEGFR1 ↓ ↑	VEGFR2 ↓ ↑	VEGFR3 ↓ ↑	其他靶点	纯度
Motesanib Diphosphate	++++ VEGFR1, IC50: 2 nM	++++ VEGFR2/Flk1, IC50: 3 nM VEGFR2, IC50: 3 nM	+++ VEGFR3, IC50: 6 nM	RET,PDGFR	98%
Tivozanib	++ VEGFR1, IC50: 30 nM	+++ VEGFR2, IC50: 6.5 nM	++ VEGFR3, IC50: 15 nM		99%+
Brivanib	+ VEGFR1, IC50: 380 nM	++ Flk1, IC50: 25 nM VEGFR2, IC50: 25 nM			99%+
Regorafenib	+++ VEGFR1, IC50: 13 nM	+++ VEGFR2, IC50: 4.2 nM	+ VEGFR3, IC50: 46 nM	RET	98%
Pazopanib	+++ VEGFR1, IC50: 10 nM	++ VEGFR2, IC50: 30 nM	+ VEGFR3, IC50: 47 nM	FGFR,c-Kit,PDGFR	99%
Sitravatinib	+++ VEGFR1 (FLT1), IC50: 6 nM	+++ VEGFR2 (KDR), IC50: 5 nM	++++ VEGFR3 (FLT4), IC50: 2 nM		99%+
Foretinib	+++ VEGFR1/FLT1, IC50: 6.8 nM	++++ KDR, IC50: 0.86 nM	++++ VEGFR3/FLT4, IC50: 2.8 nM	Tie-2	99%+
MGCD-265 analog	++++ VEGFR1, IC50: 3 nM	++++ VEGFR2, IC50: 3 nM	++++ VEGFR3, IC50: 4 nM	Tie-2	99%+
Lactate	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	85%
AEE788	+ FLT1, IC50: 59 nM	+ KDR, IC50: 77 nM		EGFR	98+%
Linifanib	++++ VEGFR1/FLT1, IC50: 3 nM	++++ VEGFR2/KDR, IC50: 4 nM	+ VEGFR3/FLT4, IC50: 190 nM	FLT3	99%+
Vatalanib 2HCl	+ VEGFR1/FLT1, IC50: 77 nM	++ VEGFR2/KDR, IC50: 37 nM VEGFR2/Flk1, IC50: 270 nM	+ VEGFR3/FLT4, IC50: 660 nM	c-Kit,c-Fms	99%+
Axitinib	++++ VEGFR1/FLT1, IC50: 0.1 nM	++++ VEGFR2/KDR, IC50: 0.2 nM VEGFR2/Flk1, IC50: 0.18 nM			98%
Dovitinib	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	99%+
ZM 306416	+ VEGFR1, IC50: 0.33 μM			Src	99%+
KRN-633	+ VEGFR1, IC50: 170 nM	+ VEGFR2, IC50: 160 nM	+ VEGFR3, IC50: 125 nM	c-Kit,BTK	98%
OSI-930	+++ FLT1, IC50: 8 nM	+++ KDR, IC50: 9 nM			99%+
Lenvatinib	++ VEGFR1/FLT1, IC50: 22 nM	++++ VEGFR2/KDR, IC50: 4.0 nM	+++ VEGFR3/FLT4, IC50: 5.2 nM		98%
NVP-BAW2881	+ hVEGFR1, IC50: 820 nM	+++ mVEGF2, IC50: 165 nM hVEGFR2, IC50: 9 nM	+ hVEGFR3, IC50: 420 nM		98%
Cediranib	+++ VEGFR1/FLT1, IC50: 5 nM	++++ VEGFR2/KDR, IC50: 0.5 nM		c-Kit	99%+
Nintedanib	++ VEGFR1, IC50: 34 nM	+++ VEGFR2, IC50: 13 nM	+++ VEGFR3, IC50: 13 nM	FLT3	99+%
BMS-794833		++ VEGFR2, IC50: 15 nM			99%+
SKLB1002		++ VEGFR2, IC50: 32 nM			98%
Cabozantinib S-malate		++++ VEGFR2/KDR, IC50: 0.035 nM			99+%
Ki8751		++++ VEGFR2, IC50: 0.9 nM		c-Kit	98+%
SU 5402		++ VEGFR2, IC50: 20 nM			98%
Rivoceranib Mesylate		++++ VEGFR2, IC50: 1 nM		RET	98+%
Ponatinib		++++ VEGFR2, IC50: 1.5 nM			98%
LY2874455		+++ VEGFR2, IC50: 7 nM			99%+
ZM323881 HCl		++++ VEGFR2, IC50: <2 nM			98%
AZD2932		+++ VEGFR-2, IC50: 8 nM		c-Kit	98%
Cabozantinib		++++ VEGFR2/KDR, IC50: 0.035 nM			98%
Sorafenib		++ VEGFR2/Flk1, IC50: 90 nM VEGFR2, IC50: 90 nM			99%
CYC-116		++ VEGFR2, Ki: 44 nM		FLT3	99%+
Golvatinib		++ VEGFR2, IC50: 16 nM			99%+
Sunitinib		+ VEGFR2 , IC50: 80 nM		FLT3	98%
RAF265		++ VEGFR2, EC50: 30 nM			99%+
PD173074					99%+
BFH772		++++ VEGFR2, IC50: 3 nM			98%
Semaxinib		+ VEGFR2/Flk1, IC50: 1.23 μM			98%
Vandetanib		++ VEGFR2, IC50: 40 nM	+ VEGFR3, IC50: 110 nM	EGFR	98%
SAR131675			++ VEGFR3, IC50: 23 nM		99%+
ENMD-2076		+ VEGFR2/KDR, IC50: 58.2 nM	++ VEGFR3/FLT4, IC50: 15.9 nM	RET,FLT3	98%
Telatinib		+++ VEGFR2, IC50: 6 nM	++++ VEGFR3, IC50: 4 nM	c-Kit	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Ponatinib 生物活性

靶点	VEGFR2 VEGFR2, IC50:1.5 nM PDGFRα PDGFRα, IC50:1.1 nM FGFR1 FGFR1, IC50:2.2 nM Abl Abl, IC50:0.37 nM
描述	The oncogenic tyrosine kinase Bcr-Abl plays a central role in the pathogenesis of chronic myelogenous leukemia, thus makes it as the therapy drug target. However, it is demonstrated that the mutations of Bcr-Abl kinase, especially the mutation of T315 residue in the gatekeeper region of the ATP-binding site, have been the most common mechanism of drug resistance, such as imatinib, nilotinib and dasatinib. Ponatinib is a multi-target inhibitor with IC50 values of 0.37nM, 1.1nM, 1.5nM, 2.2nM, 5.4nM and 12.5nM for Abl, PDGFRα, VEGFR2, FGFR1, c-Src and c-Kit, respectively. Distinguished with other Bcr-Abl inhibitors like imatinib, nilotinib and dasatinib, Ponatinib was effective against the ABLT315I mutant with significant inhibition on autophosphorylation of Abl and Abl^T315I mutant at concentration≥100nM, whereas the other compound did not. Consistent with the in vitro study, Ponatinib inhibited the cellular proliferation of Ba/F3 expressing various Bcr-Abl mutations with IC50 ranging in 0.5-36nM, as well as CML leukemia cells K562, KY01 and LAMA cell line with IC50 ranging in 0.3-3.9nM, but anti-proliferative on parental Ba/F3 cells and non CML leukemia cells at micromolar concentration. Treatment with Ponatinib at concentration>100nM for 4h can potently suppress the tyrosine phosphorylation status of BCR-ABL and the direct BCR-ABL substrate CrkL in both Ba/F3 cells expressing native BCR-ABL and Bcr-Abl^T315I mutant, further confirming the inhibition of Bcr-Abl-mediated signaling in cells expressing Bcr-Abl^T315I mutant. Oral administration of Ponatinib at dose of 5, 15 and 25mg/kg for 19 days prolonged median survival to 19.5, 26, and 30 days, respectively compared to 16 days for control group in a survival model in which mice were injected with Ba/F3 Bcr-Abl^T315I cells. Daily oral administration of 50mg/kg Ponatinib caused significant tumor regression with a 96% reduction in mean tumor volume in mice injected subcutaneously with Ba/F3 cells expressing Bcr-Abl^T315I mutant^[1].
作用机制	Ponatinib can occupy the adenine pocket of Abl, especially making favorable van der Waals interactions with the I315 mutated residue.^[1]

Ponatinib 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
22RV1		Growth Inhibition Assay		IC50=39.8398 μM	SANGER
23132-87		Growth Inhibition Assay		IC50=41.2732 μM	SANGER
5637		Growth Inhibition Assay		IC50=4.90487 μM	SANGER
639-V		Growth Inhibition Assay		IC50=2.45382 μM	SANGER

Ponatinib 动物研究

Dose	Mice^[2] (p.o.): 2.5 mg/kg - 50 mg/kg
Administration	p.o.

Ponatinib 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02551718	Acute Leukemia of Ambiguous Li... 展开 >>neage Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Refractory Adult Acute Lymphoblastic Leukemia Refractory Childhood Acute Lymphoblastic Leukemia 收起 <<	Not Applicable	Recruiting	-	United States, Washington ... 展开 >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Pamela S. Becker 206-616-1589 pbecker@u.washington.edu Principal Investigator: Pamela S. Becker 收起 <<
NCT01883219	Philadelphia Chromosome Positi... 展开 >>ve Acute Lymphocytic Leukemia Stem Cell Transplantation Minimal Residual Disease 收起 <<	Phase 2	Unknown	November 2017	China, Guangdong ... 展开 >> Department of Hematology,Nanfang Hospital, Southern Medical University Recruiting Guangzhou, Guangdong, China, 510515 Contact: Ren Lin, MD +86-020-61641613 lansinglinren@hotmail.com 收起 <<
NCT03331211	-		Recruiting	September 1, 2019	China, Guangdong ... 展开 >> Department of Hematology,Nanfang Hospital Recruiting Guangzhou, Guangdong, China, 510515 Contact: Xutao Guo 008613802426709 ext 1 gxt827@126.com 收起 <<

Ponatinib 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.88mL

0.38mL

0.19mL

9.39mL

1.88mL

0.94mL

18.78mL

3.76mL

1.88mL

Ponatinib 技术信息

CAS号	943319-70-8
分子式	C₂₉H₂₇F₃N₆O
分子量	532.559

别名	普纳替尼 (AP24534) ;AP24534
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,Store in freezer, under -20°C

溶解度

DMSO: 25 mg/mL(46.94 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

1M HCl: 50 mg/mL(93.89 mM)，配合低频超声，并调节pH至1

动物实验配方

1% CMC Na+water 30 mg/mL suspension

大规格询价

* 公司或机构名称：

* 姓名：

* 电话：

* 邮箱： * 国家/区域： * 需求量：

* 货号：

* CAS号：

* 产品名称：在线留言：

请填写此表格索取QC报告。我们很快就会发送到您的邮箱。您的信息在我们这里是安全的。*是必填项.

产品名称： * 货号：

* 姓名：

* 电话：

* 邮箱： * 公司或机构名称： * 部门：留言给我们：

摩尔计算器

计算溶液所需的质量，体积或浓度。 Ambeed 摩尔浓度计算器基于以下方程式：

浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)=质量 (g)

浓度

体积

分子量

质量

*在制备母液时，请始终参考产品标签或 MSDS / COA（在产品页面可下载）上所显示的对应批次产品的分子量。

靶点

靶点	数值

VEGFR2	VEGFR2, IC50:1.5 nM
PDGFRα	PDGFRα, IC50:1.1 nM
FGFR1	FGFR1, IC50:2.2 nM
Abl	Abl, IC50:0.37 nM

总药量计算器

动物实验：给药剂量 mg/kg 动物体重 g 动物数量只每天给药次给药天

需要的总药量： mg

工作液计算器

动物实验：给药剂量 mg/kg 动物体重 g 给药体积 μL

您需要配制的工作液浓度为：mg/mL

细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源

22RV1	Growth Inhibition Assay	IC50=39.8398 μM	SANGER
23132-87	Growth Inhibition Assay	IC50=41.2732 μM	SANGER
5637	Growth Inhibition Assay	IC50=4.90487 μM	SANGER
639-V	Growth Inhibition Assay	IC50=2.45382 μM	SANGER
647-V	Growth Inhibition Assay	IC50=0.68148 μM	SANGER
697	Growth Inhibition Assay	IC50=0.18871 μM	SANGER
769-P	Growth Inhibition Assay	IC50=20.6769 μM	SANGER
786-0	Growth Inhibition Assay	IC50=0.26228 μM	SANGER
8305C	Growth Inhibition Assay	IC50=0.39793 μM	SANGER
8505C	Growth Inhibition Assay	IC50=0.72741 μM	SANGER
8-MG-BA	Growth Inhibition Assay	IC50=0.56056 μM	SANGER
A101D	Growth Inhibition Assay	IC50=1.66781 μM	SANGER
A172	Growth Inhibition Assay	IC50=0.29577 μM	SANGER
A204	Growth Inhibition Assay	IC50=0.01218 μM	SANGER
A2058	Growth Inhibition Assay	IC50=18.8255 μM	SANGER
A253	Growth Inhibition Assay	IC50=4.97708 μM	SANGER
A2780	Growth Inhibition Assay	IC50=0.34304 μM	SANGER
A375	Growth Inhibition Assay	IC50=3.08184 μM	SANGER
A388	Growth Inhibition Assay	IC50=14.7556 μM	SANGER
A3-KAW	Growth Inhibition Assay	IC50=0.61467 μM	SANGER
A427	Growth Inhibition Assay	IC50=0.27264 μM	SANGER
A431	Growth Inhibition Assay	IC50=2.19019 μM	SANGER
A498	Growth Inhibition Assay	IC50=1.81282 μM	SANGER
A4-Fuk	Growth Inhibition Assay	IC50=0.52528 μM	SANGER
A673	Growth Inhibition Assay	IC50=1.97516 μM	SANGER
A704	Growth Inhibition Assay	IC50=1.68311 μM	SANGER
ABC-1	Growth Inhibition Assay	IC50=15.8033 μM	SANGER
ACHN	Growth Inhibition Assay	IC50=0.29323 μM	SANGER
ACN	Growth Inhibition Assay	IC50=0.34873 μM	SANGER
AGS	Growth Inhibition Assay	IC50=1.76358 μM	SANGER
ALL-PO	Growth Inhibition Assay	IC50=0.12443 μM	SANGER
AM-38	Growth Inhibition Assay	IC50=3.38051 μM	SANGER
AN3-CA	Growth Inhibition Assay	IC50=0.01873 μM	SANGER
ARH-77	Growth Inhibition Assay	IC50=1.22924 μM	SANGER
AsPC-1	Growth Inhibition Assay	IC50=7.28605 μM	SANGER
ATN-1	Growth Inhibition Assay	IC50=36.8516 μM	SANGER
AU565	Growth Inhibition Assay	IC50=34.5069 μM	SANGER
BB30-HNC	Growth Inhibition Assay	IC50=0.92469 μM	SANGER
BB49-HNC	Growth Inhibition Assay	IC50=41.2179 μM	SANGER
BB65-RCC	Growth Inhibition Assay	IC50=23.0344 μM	SANGER
BC-1	Growth Inhibition Assay	IC50=9.7899 μM	SANGER
BC-3	Growth Inhibition Assay	IC50=16.0562 μM	SANGER
BCPAP	Growth Inhibition Assay	IC50=0.36001 μM	SANGER
BE-13	Growth Inhibition Assay	IC50=0.00259 μM	SANGER
Becker	Growth Inhibition Assay	IC50=3.92849 μM	SANGER
BEN	Growth Inhibition Assay	IC50=14.9766 μM	SANGER
BFTC-905	Growth Inhibition Assay	IC50=2.90191 μM	SANGER
BFTC-909	Growth Inhibition Assay	IC50=12.9247 μM	SANGER
BHT-101	Growth Inhibition Assay	IC50=1.2349 μM	SANGER
BHY	Growth Inhibition Assay	IC50=13.339 μM	SANGER
BL-41	Growth Inhibition Assay	IC50=0.63352 μM	SANGER
BL-70	Growth Inhibition Assay	IC50=0.02199 μM	SANGER
BOKU	Growth Inhibition Assay	IC50=3.14256 μM	SANGER
BPH-1	Growth Inhibition Assay	IC50=8.85081 μM	SANGER
BT-20	Growth Inhibition Assay	IC50=29.0586 μM	SANGER
BT-474	Growth Inhibition Assay	IC50=47.4216 μM	SANGER
BxPC-3	Growth Inhibition Assay	IC50=0.34989 μM	SANGER
C2BBe1	Growth Inhibition Assay	IC50=19.4148 μM	SANGER
C32	Growth Inhibition Assay	IC50=16.9717 μM	SANGER
C-33-A	Growth Inhibition Assay	IC50=6.91688 μM	SANGER
C3A	Growth Inhibition Assay	IC50=10.3179 μM	SANGER
C-4-II	Growth Inhibition Assay	IC50=2.91353 μM	SANGER
C8166	Growth Inhibition Assay	IC50=2.78513 μM	SANGER
CA46	Growth Inhibition Assay	IC50=0.17489 μM	SANGER
Ca9-22	Growth Inhibition Assay	IC50=33.4601 μM	SANGER
CAKI-1	Growth Inhibition Assay	IC50=0.21666 μM	SANGER
CAL-120	Growth Inhibition Assay	IC50=0.47643 μM	SANGER
CAL-12T	Growth Inhibition Assay	IC50=0.73877 μM	SANGER
CAL-148	Growth Inhibition Assay	IC50=32.6665 μM	SANGER
CAL-33	Growth Inhibition Assay	IC50=18.2781 μM	SANGER
CAL-39	Growth Inhibition Assay	IC50=0.46519 μM	SANGER
CAL-51	Growth Inhibition Assay	IC50=5.62853 μM	SANGER
CAL-54	Growth Inhibition Assay	IC50=1.03959 μM	SANGER
CAL-62	Growth Inhibition Assay	IC50=22.7517 μM	SANGER
CAL-72	Growth Inhibition Assay	IC50=19.6737 μM	SANGER
CAL-85-1	Growth Inhibition Assay	IC50=0.17927 μM	SANGER
Calu-1	Growth Inhibition Assay	IC50=1.65386 μM	SANGER
Calu-3	Growth Inhibition Assay	IC50=2.78969 μM	SANGER
Calu-6	Growth Inhibition Assay	IC50=9.49703 μM	SANGER
CAMA-1	Growth Inhibition Assay	IC50=49.5543 μM	SANGER
CAPAN-1	Growth Inhibition Assay	IC50=3.87009 μM	SANGER
Capan-2	Growth Inhibition Assay	IC50=14.786 μM	SANGER
CAS-1	Growth Inhibition Assay	IC50=0.28303 μM	SANGER
Ca-Ski	Growth Inhibition Assay	IC50=0.6481 μM	SANGER
CCF-STTG1	Growth Inhibition Assay	IC50=0.22475 μM	SANGER
CCRF-CEM	Growth Inhibition Assay	IC50=9.68766 μM	SANGER
CESS	Growth Inhibition Assay	IC50=13.9489 μM	SANGER
CGTH-W-1	Growth Inhibition Assay	IC50=0.00169 μM	SANGER
ChaGo-K-1	Growth Inhibition Assay	IC50=5.35107 μM	SANGER
CHL-1	Growth Inhibition Assay	IC50=0.57463 μM	SANGER
CHP-126	Growth Inhibition Assay	IC50=21.4462 μM	SANGER
CHP-212	Growth Inhibition Assay	IC50=6.48267 μM	SANGER
CMK	Growth Inhibition Assay	IC50=4.72101 μM	SANGER
COLO-205	Growth Inhibition Assay	IC50=29.3944 μM	SANGER
COLO-320-HSR	Growth Inhibition Assay	IC50=38.3492 μM	SANGER
COLO-668	Growth Inhibition Assay	IC50=1.1649 μM	SANGER
COLO-678	Growth Inhibition Assay	IC50=2.04207 μM	SANGER
COLO-679	Growth Inhibition Assay	IC50=2.58605 μM	SANGER
COLO-680N	Growth Inhibition Assay	IC50=0.87933 μM	SANGER
COLO-792	Growth Inhibition Assay	IC50=22.7111 μM	SANGER
COLO-800	Growth Inhibition Assay	IC50=37.567 μM	SANGER
COLO-824	Growth Inhibition Assay	IC50=26.4002 μM	SANGER
COLO-829	Growth Inhibition Assay	IC50=4.77043 μM	SANGER
COR-L105	Growth Inhibition Assay	IC50=2.16373 μM	SANGER
COR-L23	Growth Inhibition Assay	IC50=21.8051 μM	SANGER
COR-L279	Growth Inhibition Assay	IC50=36.1981 μM	SANGER
COR-L88	Growth Inhibition Assay	IC50=5.76846 μM	SANGER
CP50-MEL-B	Growth Inhibition Assay	IC50=26.5675 μM	SANGER
CP66-MEL	Growth Inhibition Assay	IC50=42.1886 μM	SANGER
CTB-1	Growth Inhibition Assay	IC50=0.17316 μM	SANGER
CTV-1	Growth Inhibition Assay	IC50=0.00521 μM	SANGER
D-247MG	Growth Inhibition Assay	IC50=3.48263 μM	SANGER
D-263MG	Growth Inhibition Assay	IC50=7.45762 μM	SANGER
D-336MG	Growth Inhibition Assay	IC50=1.6294 μM	SANGER
D-392MG	Growth Inhibition Assay	IC50=0.23177 μM	SANGER
D-502MG	Growth Inhibition Assay	IC50=4.16997 μM	SANGER
D-542MG	Growth Inhibition Assay	IC50=1.85851 μM	SANGER
Daoy	Growth Inhibition Assay	IC50=11.4336 μM	SANGER
Daudi	Growth Inhibition Assay	IC50=0.02537 μM	SANGER
DB	Growth Inhibition Assay	IC50=21.6142 μM	SANGER
DBTRG-05MG	Growth Inhibition Assay	IC50=0.38054 μM	SANGER
DEL	Growth Inhibition Assay	IC50=5.27582 μM	SANGER
Detroit562	Growth Inhibition Assay	IC50=8.75455 μM	SANGER
DK-MG	Growth Inhibition Assay	IC50=3.25976 μM	SANGER
DMS-114	Growth Inhibition Assay	IC50=32.4182 μM	SANGER
DMS-273	Growth Inhibition Assay	IC50=2.75632 μM	SANGER
DMS-53	Growth Inhibition Assay	IC50=12.2649 μM	SANGER
DMS-79	Growth Inhibition Assay	IC50=20.849 μM	SANGER
DOHH-2	Growth Inhibition Assay	IC50=0.04803 μM	SANGER
DOK	Growth Inhibition Assay	IC50=3.36186 μM	SANGER
DoTc2-4510	Growth Inhibition Assay	IC50=0.54958 μM	SANGER
DSH1	Growth Inhibition Assay	IC50=7.79762 μM	SANGER
DU-145	Growth Inhibition Assay	IC50=1.08073 μM	SANGER
DU-4475	Growth Inhibition Assay	IC50=0.49511 μM	SANGER
DV-90	Growth Inhibition Assay	IC50=36.9067 μM	SANGER
EB2	Growth Inhibition Assay	IC50=0.05576 μM	SANGER
EB-3	Growth Inhibition Assay	IC50=17.576 μM	SANGER
ECC12	Growth Inhibition Assay	IC50=0.56558 μM	SANGER
ECC4	Growth Inhibition Assay	IC50=39.0814 μM	SANGER
EFE-184	Growth Inhibition Assay	IC50=12.7106 μM	SANGER
EFM-19	Growth Inhibition Assay	IC50=14.1112 μM	SANGER
EFO-21	Growth Inhibition Assay	IC50=0.30411 μM	SANGER
EFO-27	Growth Inhibition Assay	IC50=0.78733 μM	SANGER
EGI-1	Growth Inhibition Assay	IC50=27.2698 μM	SANGER
EHEB	Growth Inhibition Assay	IC50=0.52182 μM	SANGER
EoL-1-cell	Growth Inhibition Assay	IC50=0.0000000359 μM	SANGER
ES1	Growth Inhibition Assay	IC50=14.4851 μM	SANGER
ES3	Growth Inhibition Assay	IC50=2.49737 μM	SANGER
ES4	Growth Inhibition Assay	IC50=33.1705 μM	SANGER
ES5	Growth Inhibition Assay	IC50=21.6864 μM	SANGER
ES6	Growth Inhibition Assay	IC50=0.63295 μM	SANGER
ES7	Growth Inhibition Assay	IC50=1.29542 μM	SANGER
ES8	Growth Inhibition Assay	IC50=36.9318 μM	SANGER
ESS-1	Growth Inhibition Assay	IC50=0.47821 μM	SANGER
ETK-1	Growth Inhibition Assay	IC50=0.82441 μM	SANGER
EW-1	Growth Inhibition Assay	IC50=1.14128 μM	SANGER
EW-11	Growth Inhibition Assay	IC50=46.9373 μM	SANGER
EW-13	Growth Inhibition Assay	IC50=0.66779 μM	SANGER
EW-16	Growth Inhibition Assay	IC50=9.44848 μM	SANGER
EW-18	Growth Inhibition Assay	IC50=15.9979 μM	SANGER
EW-24	Growth Inhibition Assay	IC50=46.1723 μM	SANGER
EW-3	Growth Inhibition Assay	IC50=13.7163 μM	SANGER
EW-7	Growth Inhibition Assay	IC50=3.67693 μM	SANGER
FADU	Growth Inhibition Assay	IC50=48.3031 μM	SANGER
G-361	Growth Inhibition Assay	IC50=0.81897 μM	SANGER
G-401	Growth Inhibition Assay	IC50=0.93695 μM	SANGER
G-402	Growth Inhibition Assay	IC50=0.06341 μM	SANGER
GAK	Growth Inhibition Assay	IC50=27.4225 μM	SANGER
GAMG	Growth Inhibition Assay	IC50=0.73653 μM	SANGER
GB-1	Growth Inhibition Assay	IC50=0.12512 μM	SANGER
GCIY	Growth Inhibition Assay	IC50=25.2877 μM	SANGER
GCT	Growth Inhibition Assay	IC50=5.75929 μM	SANGER
GDM-1	Growth Inhibition Assay	IC50=0.01833 μM	SANGER
GI-1	Growth Inhibition Assay	IC50=4.28299 μM	SANGER
GI-ME-N	Growth Inhibition Assay	IC50=0.63069 μM	SANGER
GMS-10	Growth Inhibition Assay	IC50=5.96861 μM	SANGER
GOTO	Growth Inhibition Assay	IC50=3.22039 μM	SANGER
GP5d	Growth Inhibition Assay	IC50=9.06313 μM	SANGER
GR-ST	Growth Inhibition Assay	IC50=3.45732 μM	SANGER
GT3TKB	Growth Inhibition Assay	IC50=29.6877 μM	SANGER
H4	Growth Inhibition Assay	IC50=0.42451 μM	SANGER
HAL-01	Growth Inhibition Assay	IC50=5.14645 μM	SANGER
HC-1	Growth Inhibition Assay	IC50=0.72405 μM	SANGER
HCC1143	Growth Inhibition Assay	IC50=13.7437 μM	SANGER
HCC1395	Growth Inhibition Assay	IC50=0.95461 μM	SANGER
HCC1569	Growth Inhibition Assay	IC50=41.2885 μM	SANGER
HCC1599	Growth Inhibition Assay	IC50=37.1618 μM	SANGER
HCC1806	Growth Inhibition Assay	IC50=1.66611 μM	SANGER
HCC1954	Growth Inhibition Assay	IC50=48.1704 μM	SANGER
HCC2157	Growth Inhibition Assay	IC50=48.076 μM	SANGER
HCC2998	Growth Inhibition Assay	IC50=36.8571 μM	SANGER
HCC38	Growth Inhibition Assay	IC50=2.08433 μM	SANGER
HCC70	Growth Inhibition Assay	IC50=19.3894 μM	SANGER
HCE-4	Growth Inhibition Assay	IC50=1.09286 μM	SANGER
HCE-T	Growth Inhibition Assay	IC50=22.8606 μM	SANGER
HCT-116	Growth Inhibition Assay	IC50=0.21069 μM	SANGER
HCT-15	Growth Inhibition Assay	IC50=2.68792 μM	SANGER
HDLM-2	Growth Inhibition Assay	IC50=1.01252 μM	SANGER
HEC-1	Growth Inhibition Assay	IC50=1.33755 μM	SANGER
HEL	Growth Inhibition Assay	IC50=14.8997 μM	SANGER
HGC-27	Growth Inhibition Assay	IC50=0.29353 μM	SANGER
HL-60	Growth Inhibition Assay	IC50=1.0097 μM	SANGER
HLE	Growth Inhibition Assay	IC50=0.4186 μM	SANGER
HMV-II	Growth Inhibition Assay	IC50=5.3943 μM	SANGER
HN	Growth Inhibition Assay	IC50=11.1131 μM	SANGER
HOP-62	Growth Inhibition Assay	IC50=0.36106 μM	SANGER
HOP-92	Growth Inhibition Assay	IC50=0.65672 μM	SANGER
HOS	Growth Inhibition Assay	IC50=0.50365 μM	SANGER
HPAF-II	Growth Inhibition Assay	IC50=0.77501 μM	SANGER
Hs-578-T	Growth Inhibition Assay	IC50=4.08306 μM	SANGER
HSC-2	Growth Inhibition Assay	IC50=29.3001 μM	SANGER
HSC-3	Growth Inhibition Assay	IC50=14.6215 μM	SANGER
HSC-4	Growth Inhibition Assay	IC50=8.2872 μM	SANGER
HT-1080	Growth Inhibition Assay	IC50=8.13175 μM	SANGER
HT-1197	Growth Inhibition Assay	IC50=1.11438 μM	SANGER
HT-1376	Growth Inhibition Assay	IC50=0.86051 μM	SANGER
HT-144	Growth Inhibition Assay	IC50=0.3128 μM	SANGER
HT-29	Growth Inhibition Assay	IC50=25.7879 μM	SANGER
HT-3	Growth Inhibition Assay	IC50=28.2166 μM	SANGER
HT55	Growth Inhibition Assay	IC50=29.0565 μM	SANGER
HTC-C3	Growth Inhibition Assay	IC50=0.77451 μM	SANGER
HuCCT1	Growth Inhibition Assay	IC50=0.89548 μM	SANGER
HuH-7	Growth Inhibition Assay	IC50=0.27763 μM	SANGER
HuO-3N1	Growth Inhibition Assay	IC50=4.83281 μM	SANGER
HuO9	Growth Inhibition Assay	IC50=0.05448 μM	SANGER
HuP-T3	Growth Inhibition Assay	IC50=32.9338 μM	SANGER
HuP-T4	Growth Inhibition Assay	IC50=44.4474 μM	SANGER
HUTU-80	Growth Inhibition Assay	IC50=0.73349 μM	SANGER
IA-LM	Growth Inhibition Assay	IC50=1.40914 μM	SANGER
IGR-1	Growth Inhibition Assay	IC50=6.97826 μM	SANGER
IGROV-1	Growth Inhibition Assay	IC50=15.2317 μM	SANGER
IMR-5	Growth Inhibition Assay	IC50=1.16936 μM	SANGER
IPC-298	Growth Inhibition Assay	IC50=11.9383 μM	SANGER
IST-MEL1	Growth Inhibition Assay	IC50=0.85732 μM	SANGER
IST-MES1	Growth Inhibition Assay	IC50=0.26829 μM	SANGER
IST-SL1	Growth Inhibition Assay	IC50=17.7526 μM	SANGER
IST-SL2	Growth Inhibition Assay	IC50=0.62522 μM	SANGER
J82	Growth Inhibition Assay	IC50=0.95543 μM	SANGER
JEG-3	Growth Inhibition Assay	IC50=31.3561 μM	SANGER
JiyoyeP-2003	Growth Inhibition Assay	IC50=0.69738 μM	SANGER
J-RT3-T3-5	Growth Inhibition Assay	IC50=36.0294 μM	SANGER
JVM-2	Growth Inhibition Assay	IC50=27.6622 μM	SANGER
K052	Growth Inhibition Assay	IC50=0.5214 μM	SANGER
K5	Growth Inhibition Assay	IC50=2.71845 μM	SANGER
K-562	Growth Inhibition Assay	IC50=42.2854 μM	SANGER
KALS-1	Growth Inhibition Assay	IC50=47.2066 μM	SANGER
KARPAS-45	Growth Inhibition Assay	IC50=0.48933 μM	SANGER
KASUMI-1	Growth Inhibition Assay	IC50=0.00217 μM	SANGER
KE-37	Growth Inhibition Assay	IC50=0.96387 μM	SANGER
KG-1	Growth Inhibition Assay	IC50=0.03294 μM	SANGER
KGN	Growth Inhibition Assay	IC50=0.78081 μM	SANGER
KINGS-1	Growth Inhibition Assay	IC50=16.8273 μM	SANGER
KLE	Growth Inhibition Assay	IC50=3.9067 μM	SANGER
KM12	Growth Inhibition Assay	IC50=0.09737 μM	SANGER
KM-H2	Growth Inhibition Assay	IC50=2.0109 μM	SANGER
KMOE-2	Growth Inhibition Assay	IC50=8.87892 μM	SANGER
KNS-42	Growth Inhibition Assay	IC50=1.86266 μM	SANGER
KNS-81-FD	Growth Inhibition Assay	IC50=43.762 μM	SANGER
KOSC-2	Growth Inhibition Assay	IC50=18.7746 μM	SANGER
KP-4	Growth Inhibition Assay	IC50=39.1235 μM	SANGER
KP-N-YS	Growth Inhibition Assay	IC50=14.773 μM	SANGER
KS-1	Growth Inhibition Assay	IC50=1.28269 μM	SANGER
KU-19-19	Growth Inhibition Assay	IC50=21.8982 μM	SANGER
KU812	Growth Inhibition Assay	IC50=0.02848 μM	SANGER
KURAMOCHI	Growth Inhibition Assay	IC50=0.28419 μM	SANGER
KYSE-140	Growth Inhibition Assay	IC50=1.55741 μM	SANGER
KYSE-150	Growth Inhibition Assay	IC50=0.42415 μM	SANGER
KYSE-180	Growth Inhibition Assay	IC50=0.26891 μM	SANGER
KYSE-270	Growth Inhibition Assay	IC50=0.80529 μM	SANGER
KYSE-410	Growth Inhibition Assay	IC50=3.36287 μM	SANGER
KYSE-450	Growth Inhibition Assay	IC50=0.27329 μM	SANGER
KYSE-510	Growth Inhibition Assay	IC50=3.10995 μM	SANGER
KYSE-520	Growth Inhibition Assay	IC50=1.00494 μM	SANGER
KYSE-70	Growth Inhibition Assay	IC50=3.08882 μM	SANGER
L-363	Growth Inhibition Assay	IC50=20.0212 μM	SANGER
L-428	Growth Inhibition Assay	IC50=1.99179 μM	SANGER
L-540	Growth Inhibition Assay	IC50=0.85801 μM	SANGER
LAMA-84	Growth Inhibition Assay	IC50=0.000165 μM	SANGER
LAN-6	Growth Inhibition Assay	IC50=27.3598 μM	SANGER
LB1047-RCC	Growth Inhibition Assay	IC50=0.73538 μM	SANGER
LB2241-RCC	Growth Inhibition Assay	IC50=3.6626 μM	SANGER
LB2518-MEL	Growth Inhibition Assay	IC50=44.7937 μM	SANGER
LB373-MEL-D	Growth Inhibition Assay	IC50=26.1708 μM	SANGER
LB647-SCLC	Growth Inhibition Assay	IC50=46.2155 μM	SANGER
LB771-HNC	Growth Inhibition Assay	IC50=1.53906 μM	SANGER
LB831-BLC	Growth Inhibition Assay	IC50=1.69854 μM	SANGER
LB996-RCC	Growth Inhibition Assay	IC50=2.13817 μM	SANGER
LC-2-ad	Growth Inhibition Assay	IC50=0.24265 μM	SANGER
LC4-1	Growth Inhibition Assay	IC50=9.6257 μM	SANGER
LCLC-103H	Growth Inhibition Assay	IC50=0.58344 μM	SANGER
LCLC-97TM1	Growth Inhibition Assay	IC50=0.46195 μM	SANGER
LK-2	Growth Inhibition Assay	IC50=8.12833 μM	SANGER
LN-405	Growth Inhibition Assay	IC50=3.13518 μM	SANGER
LNCaP-Clone-FGC	Growth Inhibition Assay	IC50=25.3498 μM	SANGER
LOUCY	Growth Inhibition Assay	IC50=4.48432 μM	SANGER
LoVo	Growth Inhibition Assay	IC50=24.9282 μM	SANGER
LOXIMVI	Growth Inhibition Assay	IC50=14.7068 μM	SANGER
LP-1	Growth Inhibition Assay	IC50=34.09 μM	SANGER
LS-1034	Growth Inhibition Assay	IC50=48.7067 μM	SANGER
LS-411N	Growth Inhibition Assay	IC50=3.49692 μM	SANGER
LU-134-A	Growth Inhibition Assay	IC50=49.8085 μM	SANGER
LU-165	Growth Inhibition Assay	IC50=22.554 μM	SANGER
LU-99A	Growth Inhibition Assay	IC50=0.84701 μM	SANGER
LXF-289	Growth Inhibition Assay	IC50=8.35943 μM	SANGER
M059J	Growth Inhibition Assay	IC50=3.20173 μM	SANGER
M14	Growth Inhibition Assay	IC50=43.3189 μM	SANGER
MC116	Growth Inhibition Assay	IC50=15.1599 μM	SANGER
MC-CAR	Growth Inhibition Assay	IC50=1.58663 μM	SANGER
MCF7	Growth Inhibition Assay	IC50=11.8126 μM	SANGER
MC-IXC	Growth Inhibition Assay	IC50=2.02273 μM	SANGER
MDA-MB-134-VI	Growth Inhibition Assay	IC50=5.87536 μM	SANGER
MDA-MB-157	Growth Inhibition Assay	IC50=2.70747 μM	SANGER
MDA-MB-175-VII	Growth Inhibition Assay	IC50=27.5053 μM	SANGER
MDA-MB-231	Growth Inhibition Assay	IC50=10.2114 μM	SANGER
MDA-MB-415	Growth Inhibition Assay	IC50=12.6444 μM	SANGER
MDA-MB-453	Growth Inhibition Assay	IC50=35.1426 μM	SANGER
MDA-MB-468	Growth Inhibition Assay	IC50=40.5346 μM	SANGER
ME-180	Growth Inhibition Assay	IC50=1.37993 μM	SANGER
MEG-01	Growth Inhibition Assay	IC50=0.000128 μM	SANGER
MEL-HO	Growth Inhibition Assay	IC50=0.79449 μM	SANGER
MEL-JUSO	Growth Inhibition Assay	IC50=2.07851 μM	SANGER
MES-SA	Growth Inhibition Assay	IC50=0.24187 μM	SANGER
MFE-280	Growth Inhibition Assay	IC50=0.31453 μM	SANGER
MFE-296	Growth Inhibition Assay	IC50=0.11839 μM	SANGER
MFH-ino	Growth Inhibition Assay	IC50=0.52351 μM	SANGER
MFM-223	Growth Inhibition Assay	IC50=0.81407 μM	SANGER
MG-63	Growth Inhibition Assay	IC50=1.02616 μM	SANGER
MHH-ES-1	Growth Inhibition Assay	IC50=5.16925 μM	SANGER
MHH-NB-11	Growth Inhibition Assay	IC50=1.15368 μM	SANGER
MHH-PREB-1	Growth Inhibition Assay	IC50=1.64473 μM	SANGER
MIA-PaCa-2	Growth Inhibition Assay	IC50=1.01375 μM	SANGER
MKN1	Growth Inhibition Assay	IC50=3.18483 μM	SANGER
MKN28	Growth Inhibition Assay	IC50=1.25636 μM	SANGER
MKN45	Growth Inhibition Assay	IC50=2.73366 μM	SANGER
MKN7	Growth Inhibition Assay	IC50=7.37235 μM	SANGER
ML-2	Growth Inhibition Assay	IC50=0.9975 μM	SANGER
MLMA	Growth Inhibition Assay	IC50=0.0906 μM	SANGER
MMAC-SF	Growth Inhibition Assay	IC50=1.39595 μM	SANGER
MN-60	Growth Inhibition Assay	IC50=1.43114 μM	SANGER
MOLT-16	Growth Inhibition Assay	IC50=0.51808 μM	SANGER
MOLT-4	Growth Inhibition Assay	IC50=7.15406 μM	SANGER
MONO-MAC-6	Growth Inhibition Assay	IC50=0.00837 μM	SANGER
MPP-89	Growth Inhibition Assay	IC50=0.16933 μM	SANGER
MRK-nu-1	Growth Inhibition Assay	IC50=8.36304 μM	SANGER
MS-1	Growth Inhibition Assay	IC50=2.96769 μM	SANGER
MV-4-11	Growth Inhibition Assay	IC50=0.0000956 μM	SANGER
MZ1-PC	Growth Inhibition Assay	IC50=0.11336 μM	SANGER
MZ2-MEL	Growth Inhibition Assay	IC50=6.82011 μM	SANGER
MZ7-mel	Growth Inhibition Assay	IC50=9.0346 μM	SANGER
NALM-6	Growth Inhibition Assay	IC50=0.25543 μM	SANGER
NB1	Growth Inhibition Assay	IC50=17.3188 μM	SANGER
NB10	Growth Inhibition Assay	IC50=5.07497 μM	SANGER
NB12	Growth Inhibition Assay	IC50=3.33224 μM	SANGER
NB13	Growth Inhibition Assay	IC50=8.83796 μM	SANGER
NB5	Growth Inhibition Assay	IC50=5.9244 μM	SANGER
NB6	Growth Inhibition Assay	IC50=1.03109 μM	SANGER
NB69	Growth Inhibition Assay	IC50=5.39631 μM	SANGER
NCCIT	Growth Inhibition Assay	IC50=0.61715 μM	SANGER
NCI-H1299	Growth Inhibition Assay	IC50=5.35007 μM	SANGER
NCI-H1304	Growth Inhibition Assay	IC50=11.1576 μM	SANGER
NCI-H1355	Growth Inhibition Assay	IC50=7.77029 μM	SANGER
NCI-H1395	Growth Inhibition Assay	IC50=35.6691 μM	SANGER
NCI-H1436	Growth Inhibition Assay	IC50=26.2738 μM	SANGER
NCI-H1437	Growth Inhibition Assay	IC50=16.0667 μM	SANGER
NCI-H1522	Growth Inhibition Assay	IC50=25.9911 μM	SANGER
NCI-H1563	Growth Inhibition Assay	IC50=8.07508 μM	SANGER
NCI-H1581	Growth Inhibition Assay	IC50=0.89297 μM	SANGER
NCI-H1618	Growth Inhibition Assay	IC50=3.81875 μM	SANGER
NCI-H1623	Growth Inhibition Assay	IC50=43.464 μM	SANGER
NCI-H1648	Growth Inhibition Assay	IC50=15.5305 μM	SANGER
NCI-H1650	Growth Inhibition Assay	IC50=7.27046 μM	SANGER
NCI-H1651	Growth Inhibition Assay	IC50=2.5821 μM	SANGER
NCI-H1693	Growth Inhibition Assay	IC50=37.3233 μM	SANGER
NCI-H1703	Growth Inhibition Assay	IC50=0.19615 μM	SANGER
NCI-H1734	Growth Inhibition Assay	IC50=1.28913 μM	SANGER
NCI-H1755	Growth Inhibition Assay	IC50=0.80714 μM	SANGER
NCI-H1770	Growth Inhibition Assay	IC50=1.52054 μM	SANGER
NCI-H1792	Growth Inhibition Assay	IC50=2.56826 μM	SANGER
NCI-H1793	Growth Inhibition Assay	IC50=2.44029 μM	SANGER
NCI-H1838	Growth Inhibition Assay	IC50=49.8087 μM	SANGER
NCI-H187	Growth Inhibition Assay	IC50=38.7344 μM	SANGER
NCI-H1882	Growth Inhibition Assay	IC50=5.43364 μM	SANGER
NCI-H1993	Growth Inhibition Assay	IC50=10.5693 μM	SANGER
NCI-H2009	Growth Inhibition Assay	IC50=1.79721 μM	SANGER
NCI-H2030	Growth Inhibition Assay	IC50=0.31164 μM	SANGER
NCI-H2052	Growth Inhibition Assay	IC50=0.31484 μM	SANGER
NCI-H2081	Growth Inhibition Assay	IC50=24.0641 μM	SANGER
NCI-H2087	Growth Inhibition Assay	IC50=0.20439 μM	SANGER
NCI-H209	Growth Inhibition Assay	IC50=4.3378 μM	SANGER
NCI-H2122	Growth Inhibition Assay	IC50=35.5598 μM	SANGER
NCI-H2126	Growth Inhibition Assay	IC50=12.0218 μM	SANGER
NCI-H2170	Growth Inhibition Assay	IC50=4.66771 μM	SANGER
NCI-H2196	Growth Inhibition Assay	IC50=8.98606 μM	SANGER
NCI-H2227	Growth Inhibition Assay	IC50=39.3949 μM	SANGER
NCI-H2228	Growth Inhibition Assay	IC50=3.83126 μM	SANGER
NCI-H226	Growth Inhibition Assay	IC50=17.9546 μM	SANGER
NCI-H2342	Growth Inhibition Assay	IC50=0.18577 μM	SANGER
NCI-H2347	Growth Inhibition Assay	IC50=0.93292 μM	SANGER
NCI-H2405	Growth Inhibition Assay	IC50=1.1616 μM	SANGER
NCI-H2452	Growth Inhibition Assay	IC50=1.89074 μM	SANGER
NCI-H28	Growth Inhibition Assay	IC50=9.84933 μM	SANGER
NCI-H292	Growth Inhibition Assay	IC50=2.23951 μM	SANGER
NCI-H322M	Growth Inhibition Assay	IC50=12.3357 μM	SANGER
NCI-H345	Growth Inhibition Assay	IC50=37.3624 μM	SANGER
NCI-H358	Growth Inhibition Assay	IC50=0.95014 μM	SANGER
NCI-H441	Growth Inhibition Assay	IC50=8.193 μM	SANGER
NCI-H460	Growth Inhibition Assay	IC50=8.00694 μM	SANGER
NCI-H510A	Growth Inhibition Assay	IC50=44.708 μM	SANGER
NCI-H520	Growth Inhibition Assay	IC50=0.17732 μM	SANGER
NCI-H522	Growth Inhibition Assay	IC50=0.4527 μM	SANGER
NCI-H524	Growth Inhibition Assay	IC50=46.7185 μM	SANGER
NCI-H526	Growth Inhibition Assay	IC50=4.59293 μM	SANGER
NCI-H596	Growth Inhibition Assay	IC50=38.4489 μM	SANGER
NCI-H630	Growth Inhibition Assay	IC50=22.5363 μM	SANGER
NCI-H64	Growth Inhibition Assay	IC50=32.4179 μM	SANGER
NCI-H650	Growth Inhibition Assay	IC50=19.5899 μM	SANGER
NCI-H661	Growth Inhibition Assay	IC50=32.6501 μM	SANGER
NCI-H69	Growth Inhibition Assay	IC50=4.51793 μM	SANGER
NCI-H716	Growth Inhibition Assay	IC50=0.16266 μM	SANGER
NCI-H719	Growth Inhibition Assay	IC50=0.07888 μM	SANGER
NCI-H727	Growth Inhibition Assay	IC50=3.2658 μM	SANGER
NCI-H747	Growth Inhibition Assay	IC50=0.42137 μM	SANGER
NCI-H748	Growth Inhibition Assay	IC50=17.7035 μM	SANGER
NCI-H810	Growth Inhibition Assay	IC50=1.81606 μM	SANGER
NCI-H838	Growth Inhibition Assay	IC50=1.30615 μM	SANGER
NCI-N87	Growth Inhibition Assay	IC50=9.44731 μM	SANGER
NCI-SNU-1	Growth Inhibition Assay	IC50=0.77278 μM	SANGER
NCI-SNU-16	Growth Inhibition Assay	IC50=9.79495 μM	SANGER
NEC8	Growth Inhibition Assay	IC50=1.78995 μM	SANGER
NH-12	Growth Inhibition Assay	IC50=1.73427 μM	SANGER
NKM-1	Growth Inhibition Assay	IC50=0.00655 μM	SANGER
NMC-G1	Growth Inhibition Assay	IC50=3.71837 μM	SANGER
no-11	Growth Inhibition Assay	IC50=8.47133 μM	SANGER
NOMO-1	Growth Inhibition Assay	IC50=0.96564 μM	SANGER
NOS-1	Growth Inhibition Assay	IC50=0.24367 μM	SANGER
NTERA-S-cl-D1	Growth Inhibition Assay	IC50=1.24346 μM	SANGER
NUGC-3	Growth Inhibition Assay	IC50=25.3316 μM	SANGER
NY	Growth Inhibition Assay	IC50=0.19287 μM	SANGER
OAW-28	Growth Inhibition Assay	IC50=10.9888 μM	SANGER
OAW-42	Growth Inhibition Assay	IC50=2.09711 μM	SANGER
OCI-AML2	Growth Inhibition Assay	IC50=42.8974 μM	SANGER
OCUB-M	Growth Inhibition Assay	IC50=37.2891 μM	SANGER
OE33	Growth Inhibition Assay	IC50=25.6853 μM	SANGER
OMC-1	Growth Inhibition Assay	IC50=30.1919 μM	SANGER
ONS-76	Growth Inhibition Assay	IC50=1.52311 μM	SANGER
OPM-2	Growth Inhibition Assay	IC50=0.36473 μM	SANGER
OS-RC-2	Growth Inhibition Assay	IC50=0.58379 μM	SANGER
OVCAR-3	Growth Inhibition Assay	IC50=8.97732 μM	SANGER
OVCAR-4	Growth Inhibition Assay	IC50=0.41586 μM	SANGER
OVCAR-5	Growth Inhibition Assay	IC50=1.90675 μM	SANGER
OVCAR-8	Growth Inhibition Assay	IC50=12.1141 μM	SANGER
P12-ICHIKAWA	Growth Inhibition Assay	IC50=8.7894 μM	SANGER
P30-OHK	Growth Inhibition Assay	IC50=0.15672 μM	SANGER
PA-1	Growth Inhibition Assay	IC50=25.6833 μM	SANGER
PANC-03-27	Growth Inhibition Assay	IC50=3.81916 μM	SANGER
PANC-08-13	Growth Inhibition Assay	IC50=2.33235 μM	SANGER
PANC-10-05	Growth Inhibition Assay	IC50=40.1828 μM	SANGER
PC-14	Growth Inhibition Assay	IC50=3.66437 μM	SANGER
PC-3	Growth Inhibition Assay	IC50=44.4347 μM	SANGER
PF-382	Growth Inhibition Assay	IC50=0.20873 μM	SANGER
PFSK-1	Growth Inhibition Assay	IC50=31.2659 μM	SANGER
PLC-PRF-5	Growth Inhibition Assay	IC50=20.3906 μM	SANGER
QIMR-WIL	Growth Inhibition Assay	IC50=0.33424 μM	SANGER
Raji	Growth Inhibition Assay	IC50=12.614 μM	SANGER
Ramos-2G6-4C10	Growth Inhibition Assay	IC50=2.64807 μM	SANGER
RCC10RGB	Growth Inhibition Assay	IC50=2.18576 μM	SANGER
RCM-1	Growth Inhibition Assay	IC50=25.9656 μM	SANGER
RD	Growth Inhibition Assay	IC50=31.5115 μM	SANGER
REH	Growth Inhibition Assay	IC50=13.8982 μM	SANGER
RERF-LC-MS	Growth Inhibition Assay	IC50=43.9281 μM	SANGER
RKO	Growth Inhibition Assay	IC50=2.42029 μM	SANGER
RL	Growth Inhibition Assay	IC50=28.5911 μM	SANGER
RL95-2	Growth Inhibition Assay	IC50=1.71463 μM	SANGER
RMG-I	Growth Inhibition Assay	IC50=18.6947 μM	SANGER
RO82-W-1	Growth Inhibition Assay	IC50=0.59615 μM	SANGER
RPMI-2650	Growth Inhibition Assay	IC50=1.72719 μM	SANGER
RPMI-6666	Growth Inhibition Assay	IC50=0.52135 μM	SANGER
RPMI-7951	Growth Inhibition Assay	IC50=41.2075 μM	SANGER
RPMI-8402	Growth Inhibition Assay	IC50=8.89926 μM	SANGER
RS4-11	Growth Inhibition Assay	IC50=4.11255 μM	SANGER
RT-112	Growth Inhibition Assay	IC50=0.23795 μM	SANGER
RT4	Growth Inhibition Assay	IC50=0.45111 μM	SANGER
RVH-421	Growth Inhibition Assay	IC50=12.4904 μM	SANGER
RXF393	Growth Inhibition Assay	IC50=5.48494 μM	SANGER
S-117	Growth Inhibition Assay	IC50=48.3815 μM	SANGER
Saos-2	Growth Inhibition Assay	IC50=20.9556 μM	SANGER
SAS	Growth Inhibition Assay	IC50=40.096 μM	SANGER
SBC-1	Growth Inhibition Assay	IC50=10.072 μM	SANGER
SBC-5	Growth Inhibition Assay	IC50=17.1479 μM	SANGER
SCC-15	Growth Inhibition Assay	IC50=16.2825 μM	SANGER
SCC-25	Growth Inhibition Assay	IC50=1.23536 μM	SANGER
SCC-4	Growth Inhibition Assay	IC50=18.3229 μM	SANGER
SCC-9	Growth Inhibition Assay	IC50=4.53172 μM	SANGER
SF126	Growth Inhibition Assay	IC50=0.17063 μM	SANGER
SF268	Growth Inhibition Assay	IC50=0.4486 μM	SANGER
SF295	Growth Inhibition Assay	IC50=3.61552 μM	SANGER
SF539	Growth Inhibition Assay	IC50=5.09959 μM	SANGER
SH-4	Growth Inhibition Assay	IC50=1.02244 μM	SANGER
SHP-77	Growth Inhibition Assay	IC50=21.6122 μM	SANGER
SIG-M5	Growth Inhibition Assay	IC50=0.1337 μM	SANGER
SiHa	Growth Inhibition Assay	IC50=23.3968 μM	SANGER
SIMA	Growth Inhibition Assay	IC50=1.48687 μM	SANGER
SJRH30	Growth Inhibition Assay	IC50=12.2299 μM	SANGER
SJSA-1	Growth Inhibition Assay	IC50=2.41271 μM	SANGER
SK-CO-1	Growth Inhibition Assay	IC50=10.777 μM	SANGER
SKG-IIIa	Growth Inhibition Assay	IC50=14.8862 μM	SANGER
SK-HEP-1	Growth Inhibition Assay	IC50=0.33368 μM	SANGER
SK-LMS-1	Growth Inhibition Assay	IC50=0.6647 μM	SANGER
SK-LU-1	Growth Inhibition Assay	IC50=0.31466 μM	SANGER
SK-MEL-2	Growth Inhibition Assay	IC50=1.90271 μM	SANGER
SK-MEL-24	Growth Inhibition Assay	IC50=0.39791 μM	SANGER
SK-MEL-28	Growth Inhibition Assay	IC50=7.40798 μM	SANGER
SK-MEL-3	Growth Inhibition Assay	IC50=1.63902 μM	SANGER
SK-MEL-30	Growth Inhibition Assay	IC50=3.65921 μM	SANGER
SK-MES-1	Growth Inhibition Assay	IC50=3.56433 μM	SANGER
SK-N-AS	Growth Inhibition Assay	IC50=47.888 μM	SANGER
SK-NEP-1	Growth Inhibition Assay	IC50=1.83767 μM	SANGER
SK-OV-3	Growth Inhibition Assay	IC50=4.48149 μM	SANGER
SK-PN-DW	Growth Inhibition Assay	IC50=4.07974 μM	SANGER
SK-UT-1	Growth Inhibition Assay	IC50=2.33184 μM	SANGER
SN12C	Growth Inhibition Assay	IC50=2.58487 μM	SANGER
SNB75	Growth Inhibition Assay	IC50=2.88535 μM	SANGER
SNG-M	Growth Inhibition Assay	IC50=1.95858 μM	SANGER
SNU-387	Growth Inhibition Assay	IC50=8.63246 μM	SANGER
SNU-423	Growth Inhibition Assay	IC50=20.1043 μM	SANGER
SNU-449	Growth Inhibition Assay	IC50=0.29964 μM	SANGER
SNU-475	Growth Inhibition Assay	IC50=5.47171 μM	SANGER
SNU-C1	Growth Inhibition Assay	IC50=35.171 μM	SANGER
SNU-C2B	Growth Inhibition Assay	IC50=7.29571 μM	SANGER
SR	Growth Inhibition Assay	IC50=4.70048 μM	SANGER
ST486	Growth Inhibition Assay	IC50=2.41048 μM	SANGER
SU-DHL-1	Growth Inhibition Assay	IC50=0.06379 μM	SANGER
SUP-T1	Growth Inhibition Assay	IC50=0.09982 μM	SANGER
SW1088	Growth Inhibition Assay	IC50=0.4439 μM	SANGER
SW13	Growth Inhibition Assay	IC50=35.4076 μM	SANGER
SW1417	Growth Inhibition Assay	IC50=0.52781 μM	SANGER
SW1463	Growth Inhibition Assay	IC50=20.4525 μM	SANGER
SW1573	Growth Inhibition Assay	IC50=5.63534 μM	SANGER
SW1710	Growth Inhibition Assay	IC50=0.36455 μM	SANGER
SW1783	Growth Inhibition Assay	IC50=27.7783 μM	SANGER
SW1990	Growth Inhibition Assay	IC50=10.328 μM	SANGER
SW48	Growth Inhibition Assay	IC50=1.54243 μM	SANGER
SW620	Growth Inhibition Assay	IC50=7.38205 μM	SANGER
SW626	Growth Inhibition Assay	IC50=1.5816 μM	SANGER
SW756	Growth Inhibition Assay	IC50=43.0388 μM	SANGER
SW780	Growth Inhibition Assay	IC50=0.42346 μM	SANGER
SW837	Growth Inhibition Assay	IC50=21.4939 μM	SANGER
SW872	Growth Inhibition Assay	IC50=0.99775 μM	SANGER
SW948	Growth Inhibition Assay	IC50=8.10744 μM	SANGER
SW954	Growth Inhibition Assay	IC50=8.76832 μM	SANGER
SW962	Growth Inhibition Assay	IC50=6.65774 μM	SANGER
SW982	Growth Inhibition Assay	IC50=0.29978 μM	SANGER
T47D	Growth Inhibition Assay	IC50=29.8582 μM	SANGER
T84	Growth Inhibition Assay	IC50=21.9819 μM	SANGER
T98G	Growth Inhibition Assay	IC50=0.19318 μM	SANGER
TCCSUP	Growth Inhibition Assay	IC50=1.01732 μM	SANGER
TE-10	Growth Inhibition Assay	IC50=3.17362 μM	SANGER
TE-11	Growth Inhibition Assay	IC50=6.55182 μM	SANGER
TE-12	Growth Inhibition Assay	IC50=0.55735 μM	SANGER
TE-15	Growth Inhibition Assay	IC50=0.26091 μM	SANGER
TE-441-T	Growth Inhibition Assay	IC50=3.73028 μM	SANGER
TE-5	Growth Inhibition Assay	IC50=45.9581 μM	SANGER
TE-6	Growth Inhibition Assay	IC50=7.44908 μM	SANGER
TE-8	Growth Inhibition Assay	IC50=3.49333 μM	SANGER
TE-9	Growth Inhibition Assay	IC50=8.81062 μM	SANGER
TGBC1TKB	Growth Inhibition Assay	IC50=43.9099 μM	SANGER
TGBC24TKB	Growth Inhibition Assay	IC50=29.1831 μM	SANGER
THP-1	Growth Inhibition Assay	IC50=37.2868 μM	SANGER
TK10	Growth Inhibition Assay	IC50=28.6535 μM	SANGER
TT	Growth Inhibition Assay	IC50=16.5888 μM	SANGER
TUR	Growth Inhibition Assay	IC50=10.1657 μM	SANGER
U031	Growth Inhibition Assay	IC50=14.4085 μM	SANGER
U-118-MG	Growth Inhibition Assay	IC50=2.58872 μM	SANGER
U251	Growth Inhibition Assay	IC50=24.0668 μM	SANGER
U-266	Growth Inhibition Assay	IC50=1.09633 μM	SANGER
U-2-OS	Growth Inhibition Assay	IC50=0.85846 μM	SANGER
U-698-M	Growth Inhibition Assay	IC50=0.71063 μM	SANGER
UACC-257	Growth Inhibition Assay	IC50=27.6878 μM	SANGER
UACC-62	Growth Inhibition Assay	IC50=2.08855 μM	SANGER
UMC-11	Growth Inhibition Assay	IC50=37.2503 μM	SANGER
UM-UC-3	Growth Inhibition Assay	IC50=36.8675 μM	SANGER
VA-ES-BJ	Growth Inhibition Assay	IC50=11.7195 μM	SANGER
VM-CUB-1	Growth Inhibition Assay	IC50=11.9091 μM	SANGER
VMRC-RCZ	Growth Inhibition Assay	IC50=0.49904 μM	SANGER
WM-115	Growth Inhibition Assay	IC50=17.8085 μM	SANGER
WSU-NHL	Growth Inhibition Assay	IC50=0.70887 μM	SANGER
YAPC	Growth Inhibition Assay	IC50=36.9654 μM	SANGER
YKG-1	Growth Inhibition Assay	IC50=13.3749 μM	SANGER
YT	Growth Inhibition Assay	IC50=0.26974 μM	SANGER

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02551718	Acute Leukemia of Ambiguous Li... 展开 >>neage Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Refractory Adult Acute Lymphoblastic Leukemia Refractory Childhood Acute Lymphoblastic Leukemia 收起 <<	Not Applicable	Recruiting	-	United States, Washington ... 展开 >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Pamela S. Becker 206-616-1589 pbecker@u.washington.edu Principal Investigator: Pamela S. Becker 收起 <<
NCT01883219	Philadelphia Chromosome Positi... 展开 >>ve Acute Lymphocytic Leukemia Stem Cell Transplantation Minimal Residual Disease 收起 <<	Phase 2	Unknown	November 2017	China, Guangdong ... 展开 >> Department of Hematology,Nanfang Hospital, Southern Medical University Recruiting Guangzhou, Guangdong, China, 510515 Contact: Ren Lin, MD +86-020-61641613 lansinglinren@hotmail.com 收起 <<
NCT03331211	-		Recruiting	September 1, 2019	China, Guangdong ... 展开 >> Department of Hematology,Nanfang Hospital Recruiting Guangzhou, Guangdong, China, 510515 Contact: Xutao Guo 008613802426709 ext 1 gxt827@126.com 收起 <<
NCT03624530	Philadelphia Chromosome Positi... 展开 >>ve Acute Lymphocytic Leukemia Tyrosine Kinase Inhibitor Minimal Residual Disease Allogeneic Hematopoietic Stem Cell Transplantation 收起 <<	Phase 2 Phase 3	Recruiting	July 2022	China, Guangdong ... 展开 >> Department of Hematology,Nanfang Hospital, Southern Medical University Recruiting Guangzhou, Guangdong, China, 510515 Contact: Li Xuan +86-020-62787883 356135708@qq.com Principal Investigator: Qifa Liu 收起 <<
NCT03746054	Chronic Myeloid Leukemia (CML)	Phase 3	Not yet recruiting	March 2023	-
NCT02779283	Acute Lymphoblastic Leukemia ... 展开 >> Acute Myeloid Leukemia 收起 <<	Phase 1	Recruiting	June 1, 2019	United States, Oregon ... 展开 >> OHSU Knight Cancer Institute Recruiting Portland, Oregon, United States, 97239 Contact: Stephen E. Spurgeon 503-494-8950 spurgeos@ohsu.edu Principal Investigator: Stephen E. Spurgeon 收起 <<
NCT02455024	-		Recruiting	September 30, 2021	United States, New Jersey ... 展开 >> John Theurer Cancer Center at Hackensack UMC (Site 128) Recruiting Hackensack, New Jersey, United States, 07601 Principal Investigator: Stefan Faderl, MD United States, New York Hudson Valley Hematology Oncology Associates (Site 236) Recruiting Hawthorne, New York, United States, 10532 Principal Investigator: Karen Seiter, M.D. 收起 <<
NCT02448095	-		Recruiting	December 2018	Italy ... 展开 >> UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro Recruiting Bari, Italy Contact: Giorgina Specchia Principal Investigator: Giorgina Specchia IRCCS_AOU San Martino-IST.Clinica Ematologica Recruiting Genova, Italy Contact: Marco Gobbi Principal Investigator: Marco Gobbi ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE Recruiting Lecce, Italy Contact: Nicola Di Renzo Principal Investigator: Nicola Di Renzo Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia- Padiglione Marcora 2° piano Recruiting Milano, Italy Contact: Carmen Fava Principal Investigator: Carmen Fava Azienda Ospedaliera "S.Gerardo" Recruiting Monza, Italy Contact: Carlo Gambacorti Passerini Principal Investigator: Carlo Gambacorti Passerini S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro Recruiting Novara, Italy Contact: Gianluca Gaidano Principal Investigator: Gianluca Gaidano Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga-Medicina Interna 2 - Orbassano Recruiting Orbassano, Italy Contact: Carmen Fava S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo Recruiting Pavia, Italy Contact: Ester Orlandi Principal Investigator: Ester Orlandi Dipartimento Emato-Oncologia A.O."Bianchi-Melacrino-Morelli" Recruiting Reggio Calabria, Italy Contact: Bruno Martino Principal Investigator: Bruno Martino U.O.C. Ematologia - Ospedale S. Eugenio Recruiting Roma, Italy Contact: Elisabetta Abruzzese Principal Investigator: Elisabetta Abruzzese 收起 <<
NCT03515785	-		Withdrawn(Revisiting the avail... 展开 >>ability of patients with Ph+ ALL that would meet the in-/exclusion criteria of the study led to the decision not to move forward.) 收起 <<	March 2021	Czechia ... 展开 >> Ihbt/Úhkt Praha, Czechia, 128 00 France University Hospital Amiens Amiens, France, 80080 University Hospital Angers Angers, France, 49100 University Hospital Bordeaux Bordeaux, France, 33000 University Hospital Grenoble Grenoble, France, 38700 University Hospital Lyon Lyon, France, 69361 University Cancer Institute Oncopole Toulouse, France, 31059 Germany University Hospital Halle/Saale Halle/Saale, Germany, 06120 University Hospital Munich Munich, Germany, 81377 University Hospital Rostock Rostock, Germany, 18057 收起 <<
NCT02767063	Leukemia, Myeloid, Chronic-Pha... 展开 >>se 收起 <<	Phase 1 Phase 2	Recruiting	June 2021	France ... 展开 >> Martine GARDEMBAS Recruiting Angers, France Contact: Martine GARDEMBAS 02.41.35.44.75 MaGardembas@chu-angers.fr Pascale CONY.MAKHOUL Recruiting Annecy, France Contact: Pascale CONY.MAKHOUL 04.50.63.64.31 pconymakhoul@ch-annecygenevois.fr Thorsten BRAUN Recruiting Bobigny, France Contact: Thorsten BRAUN 01.48.95.54.58 Thorsten.braun@avc.aphp.fr Etienne Recruiting Bordeaux, France Contact: Gabriel Etienne 05.56.33.04.76 G.Etienne@bordeaux.unicancer.fr CHU Côte de Nacre Not yet recruiting Caen, France Contact: Hyacynthe Johnson-Ansah 02.31.27.25.39 Johnsonansah-a@chu-caen.fr CHU Estaing Not yet recruiting Clermont-Ferrand, France Contact: Marc BERGER mberger@chu-clermontferrand.fr CH Henri Mondor Recruiting Créteil, France Contact: ROY Lydia Rousselot Recruiting Le Chesnay, France Contact: Philippe Rousselot 01.39.63.89.09 phrousselot@ch-versailles.fr CHU Lille Recruiting Lille, France Contact: COITEUX Valérie CHU de LIMOGES Not yet recruiting Limoges, France Contact: Amélie PENOT 05.55.05.66.42 Amelie.penot@chu-limoges.fr Franck NICOLINI Recruiting Lyon, France Contact: Franck NICOLINI 04.72.11.74.01 franck.nicolini@chu-lyon.fr Institut P Calmette Recruiting Marseille, France Contact: CHARBONNIER Aude Viviane DUBRUILLE Recruiting Nantes, France Contact: Viviane DUBRUILLE 02.40.08.32.71 Viviane.dubruille@chu-nantes.fr Hopital l'Archet Not yet recruiting Nice, France Contact: Laurence LEGROS 04.92.03.58.41 legros.l@chu-nice.fr Eric JOURDAN Recruiting Nimes, France Contact: Eric JOURDAN 04.66.68.32.31 eric.jourdan@chu-nimes.fr Hôpital La Source Recruiting Orléans, France Contact: BENBRAHIM Omar Delphine REA _St louis Recruiting Paris, France Contact: Delphine REA 01.42.49.96.49 delphine.rea@aphp.fr Simona LAPUSAN_St Antoine Recruiting Paris, France Contact: Simona LAPUSAN 01.49.28.34.42 Simona.lapusan@sat.aphp.fr Cayssials Recruiting Poitiers, France Contact: Emilie Cayssials : 05.49.44. 44.72 e.cayssials@chu-poitiers.fr CHU de Rennes - Pontchaillou Recruiting Rennes, France Contact: ESCOFFRE-BARBE Martine Hôpital René Huguenin Not yet recruiting Saint-Cloud, France Contact: Sylvie GLAISNER 01.47.11.15.30 Sylvie.glaisner@curie.net Institut Universitaire contre le Cancer Not yet recruiting Toulouse, France Contact: Françoise HUGUET 05.31.15.63.56 Huguet.françoise@iuct-oncopole.fr CHU Tours Not yet recruiting Tours, France Contact: DARTIGEAS Caroline 收起 <<
NCT03263572	Malignant Neoplasms Stated as ... 展开 >>Primary Lymphoid Haematopoietic Acute Lymphoblastic Leukemia 收起 <<	Phase 2	Recruiting	November 2023	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact ejabbour@mdanderson.org 收起 <<
NCT01620216	Acute Myeloid Leukemia Arising... 展开 >> From Previous Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia Myelodysplastic Syndrome Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Refractory Adult Acute Lymphoblastic Leukemia 收起 <<	Phase 2	Recruiting	March 30, 2019	United States, Maryland ... 展开 >> National Heart Lung and Blood Institute Not yet recruiting Bethesda, Maryland, United States, 20824 Contact: Christopher S. Hourigan 301-803-8029 hourigan@nih.gov Principal Investigator: Christopher S. Hourigan United States, Oregon OHSU Knight Cancer Institute Not yet recruiting Portland, Oregon, United States, 97239 Contact: Marc Loriaux 503-494-9383 loriauxm@ohsu.edu Principal Investigator: Marc Loriaux United States, Texas UT Southwestern/Simmons Cancer Center-Dallas Recruiting Dallas, Texas, United States, 75390 Contact: Robert H. Collins 214-648-4155 robert.collins@utsouthwestern.edu Principal Investigator: Robert H. Collins United States, Utah Huntsman Cancer Institute/University of Utah Not yet recruiting Salt Lake City, Utah, United States, 84112 Contact: Tibor J. Kovacsovics 801-585-3229 tibor.kovacsovics@hci.utah.edu Principal Investigator: Tibor J. Kovacsovics 收起 <<
NCT03576547	Blast Phase Chronic Myelogenou... 展开 >>s Leukemia, BCR-ABL1 Positive Philadelphia Chromosome Positive Recurrent Acute Lymphoblastic Leukemia Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Refractory Acute Lymphoblastic Leukemia Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive t(9;22) 收起 <<	Phase 1 Phase 2	Recruiting	January 31, 2019	United States, Texas ... 展开 >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Farhad Ravandi-Kashani 713-745-0394 Principal Investigator: Farhad Ravandi-Kashani 收起 <<
NCT03147612	Acute Lymphoblastic Leukemia ... 展开 >> Acute Myeloid Leukemia With BCR-ABL1 Philadelphia Chromosome Positive Recurrent Acute Lymphoblastic Leukemia Refractory Acute Lymphoblastic Leukemia 收起 <<	Phase 2	Recruiting	February 8, 2024	United States, Texas ... 展开 >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Elias Jabbour 713-792-4764 Principal Investigator: Elias Jabbour 收起 <<
NCT01424982	Acute Lymphoblastic Leukemia ... 展开 >> Adult Acute Lymphoblastic Leukemia in Complete Remission B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 Philadelphia Chromosome Positive Untreated Adult Acute Lymphoblastic Leukemia 收起 <<	Phase 2	Recruiting	October 31, 2021	United States, Texas ... 展开 >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Elias Jabbour 713-792-7026 Principal Investigator: Elias Jabbour 收起 <<
NCT03678454	-		Recruiting	November 30, 2019	Belgium ... 展开 >> ZNA Stuyvenberg Recruiting Antwerpen, Belgium, 2060 UZ Antwerpen Recruiting Antwerpen, Belgium, 2650 AZ Klina Recruiting Brasschaat, Belgium, 2930 AZ St-Jan Brugge Recruiting Brugge, Belgium, 8000 Institut Jules Bordet Recruiting Brussels, Belgium, 1000 CHU Brugmann Recruiting Brussels, Belgium, 1020 Hopital Erasme Recruiting Brussels, Belgium, 1070 UZ Brussel Recruiting Brussels, Belgium, 1090 Clinique universitaires Saint-Luc Recruiting Brussels, Belgium, 1200 Ziekenhuis Oost Limburg (ZOL) Recruiting Gent, Belgium, 3600 Hopital Jolimont Recruiting Haine-Saint-Paul, Belgium, 7100 Jessa Ziekenhuis Recruiting Hasselt, Belgium, 3500 AZ Groeninge Recruiting Kortrijk, Belgium, 8500 UZ Leuven Recruiting Leuven, Belgium, 3000 CHU Sart Tilman Liège Recruiting Liège, Belgium, 4000 CHU Charleroi Vésale Recruiting Montigny-le-Tilleul, Belgium, 6110 AZ Turnhout St-Elisabeth Recruiting Turnhout, Belgium, 2300 CHR La Tourelle Recruiting Verviers, Belgium, 4800 CHU/UCL Namur Mont-Godinne Recruiting Yvoir, Belgium, 5530 收起 <<
NCT02776605	ALL	Phase 2	Recruiting	December 2020	Spain ... 展开 >> Hospital Germans Trias i Pujol Recruiting Badalona, Spain Contact: Josep Mª Ribera, Dr jribera@iconcologia.net Hospital Clinic Recruiting Barcelona, Spain, 08036 Contact: Jordi Esteve, Dr JESTEVE@clinic.ub.es Hospital Universitario Vall d'Hebron Recruiting Barcelona, Spain Contact: Pere Barba, Dr pebarba@vhebron.net Hospital 12 de Octubre Recruiting Madrid, Spain Contact: Mª Pilar Martinez Sánchez, Dr mpmartinezs.hdoc@salud.madrid.org Hospital Virgen de la Victoria Recruiting Málaga, Spain Contact: Mª José Moreno, Dr mjmorenorico@hotmail.com Hospital Clinico Universitario de Salamanca Recruiting Salamanca, Spain Contact: Jesús Maria Hernández Rivas, Dr jmhr@usal.es Hospital Marques de Valdecilla Recruiting Santander, Spain Contact: Mª Aranzazu Bermudez, Dr mbermudez@humv.es C H Santiago de Compostela Recruiting Santiago de Compostela, Spain Contact: Natalia Alonso, Dr natalia.alonso.vence@sergas.es Hospital Virgen del Rocio Recruiting Sevilla, Spain Contact: Jose Gonzalez Campos, Dr jose.gonzalez.sspa@juntadeandalucia.es Hospital Clinico de Valencia Recruiting Valencia, Spain Contact: Mª del Mar Tormo, Dr tormo_mar@gva.es Hospital La Fe Recruiting Valencia, Spain Contact: Pau Montesinos, Dr montesinos_pau@gva.es 收起 <<
NCT03704688	Non Small Cell Lung Cancer ... 展开 >> KRAS Gene Mutation 收起 <<	Phase 1 Phase 2	Recruiting	April 2021	United States, New Jersey ... 展开 >> Memoral Sloan Kettering Basking Ridge Recruiting Basking Ridge, New Jersey, United States, 07920 Contact: Kathryn Arbour, MD 646-449-1775 United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Recruiting Commack, New York, United States, 11725 Contact: Kathryn Arbour, MD 646-449-1775 Memoral Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Kathryn Arbour, MD 646-449-1775 Memorial Sloan Kettering @ Rockville Recruiting Rockville Centre, New York, United States, 11570 Contact: Kathryn Arbour, MD 646-449-1775 收起 <<
NCT00660920	Chronic Myelogenous Leukemia ... 展开 >> Hematologic Malignancies 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> ARIAD Investigational Site #075 San Francisco, California, United States, 94143 United States, Michigan ARIAD Investigational Site #011 Ann Arbor, Michigan, United States, 48109 United States, Oregon ARIAD Investigational Site #048 Portland, Oregon, United States, 97239 United States, Tennessee ARIAD Investigational Site #076 Nashville, Tennessee, United States, 37203 United States, Texas ARIAD Investigational Site #005 Houston, Texas, United States, 70030 收起 <<
NCT01746836	Chronic Phase Chronic Myelogen... 展开 >>ous Leukemia, BCR-ABL1 Positive Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive 收起 <<	Phase 2	Active, not recruiting	January 31, 2019	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01838642	Thyroid Neoplasms	Phase 2	Terminated(Recruiting halted p... 展开 >>rematurely and will not resume. New study to open soon.) 收起 <<	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01650805	-		Terminated(Study terminated ba... 展开 >>sed on evaluation of safety data.) 收起 <<	-	-
NCT01838642	-		Terminated(Recruiting halted p... 展开 >>rematurely and will not resume. New study to open soon.) 收起 <<	-	-
NCT01207440	Chronic Myeloid Leukemia ... 展开 >> Ph+ Acute Lymphoblastic Leukemia 收起 <<	Phase 2	Active, not recruiting	January 30, 2019	-
NCT01549548	-		-	-	United States, Oregon ... 展开 >> OHSU Knight Cancer Institute Portland, Oregon, United States, 97239 收起 <<
NCT01641107	Philadelphia Positive ... 展开 >> BCR-ABL Positive Acute Lymphoblastic Leukemia 收起 <<	Phase 2	Active, not recruiting	November 2019	Italy ... 展开 >> S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo Alessandria, Italy Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI Ancona, Italy Dipartimento Area Medica - Presidio Ospedaliero "C. e G.Mazzoni" Ascoli, Italy Az.Ospedaliera S.G.Moscati Avellino, Italy Azienda Ospedaliera - Papa Giovanni XXIII Bergamo, Italy Istituto di Ematologia "Lorenzo e A. Seragnoli" - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi Bologna, Italy ASL N.8 - Ospedale "A. Businco" - Struttura Complessa di Ematologia e CTMO Cagliari, Italy Università di Catania - Cattedra di Ematologia - Ospedale "Ferrarotto" Catania, Italy Azienda Ospedaliero Universitaria Arcispedale Sant'Anna Dipartimento di Scienze Mediche Sezione di Ematologia e Fisiopatologia dell'Emostasi Ferrara, Italy Policlinico di Careggi Firenze, Italy Divisione Ematologia 1 - Azienda Ospedaliera Universitaria "San Martino" Genova, Italy ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE Lecce, Italy Unità Operativa Complessa - Medicina Generale - Sezione di Ematologia - Ospedale Versilia USL 12 Toscana Lido di Camaiore, Italy Istituto Scientifico Romagnoli per lo Studio e la Cura dei Tumori- IRST Meldola, Italy U.O. di Ematologia- Ospedale dell'Angelo - Mestre Mestre, Italy Ospedale Niguarda " Ca Granda" Milano, Italy UO Ematologia - AOU Policlinico di Modena Modena, Italy S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro Novara, Italy Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga-Medicina Interna 2 Orbassano, Italy Università degli Studi di Padova - Ematologia ed Immunologia Clinica Padova, Italy Ospedali Riuniti "Villa Sofia-Cervello" Palermo, Italy S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo Pavia, Italy Sezione di Ematologia ed Immunologia Clinica - Ospedale S.Maria della Misericordia Perugia, Italy Div. di Ematologia di Muraglia - CTMO Ospedale San Salvator Pesaro, Italy U.O. Ematologia Clinica - Azienda USL di Pescara Pescara, Italy Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale di Piacenza Piacenza, Italy Università di Pisa - Azienda Ospedaliera Pisana - Dipartimento di Oncologia, dei Trapianti e delle nuove Tecnologie in Medicina - Divisione di Ematologia Pisa, Italy Dipartimento Oncologico - Ospedale S.Maria delle Croci Ravenna, Italy Dipartimento Emato-Oncologia A.O."Bianchi-Melacrino-Morelli" Reggio Calabria, Italy Ospedale "Infermi" Rimini, Italy Complesso Ospedaliero S. Giovanni Addolorata Roma, Italy S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena Roma, Italy U.O.C. Ematologia - Ospedale S.Eugenio Roma, Italy Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia Roma, Italy Università degli Studi - Policlinico di Tor Vergata Roma, Italy UOC di Ematologia e Trapianti di Cellule Staminali Emopoietiche - AOU San Giovanni di Dio e Ruggi D'Aragona Salerno, Italy U.O.C. Ematologia e Trapianti - A.O. Senese - Policlinico " Le Scotte" Siena, Italy Dipartimento di Oncologia ed Ematologia S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino San Giovanni Battista Torino, Italy Azienda U.L.S.S.9 - U.O. di Ematologia Treviso, Italy Clinica Ematologica - Policlinico Universitario Udine, Italy Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi Verona, Italy ULSS N.6 Osp. S. Bortolo Vicenza, Italy 收起 <<
NCT01650805	Chronic Myeloid Leukemia	Phase 3	Terminated(Study terminated ba... 展开 >>sed on evaluation of safety data.) 收起 <<	-	-
NCT03589326	Lymphoblastic Leukemia, Acute,... 展开 >> Adult Acute Lymphoid Leukemia Leukemia, Acute Lymphoblastic Leukemia, Lymphoblastic Ph1 Chromosome Leukemia, Lymphoblastic, Acute, Philadelphia-Positive 收起 <<	Phase 3	Recruiting	July 4, 2026	United States, California ... 展开 >> City of Hope - Duarte Recruiting Duarte, California, United States, 91010 United States, South Carolina Saint Francis Cancer Center Recruiting Greenville, South Carolina, United States, 29607 United States, Texas The University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030-4000 Methodist Hospital Recruiting San Antonio, Texas, United States, 78229 收起 <<
NCT02265341	Malignant Hepatobiliary Neopla... 展开 >>sm 收起 <<	Phase 2	Active, not recruiting	October 15, 2019	United States, Arizona ... 展开 >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 收起 <<
NCT02467270	Myeloid Leukemia, Chronic, Chr... 展开 >>onic Phase 收起 <<	Phase 2	Recruiting	December 31, 2022	-
NCT02981784	-		Completed	-	France ... 展开 >> Centre Hospitalier Lyon-Sud Pierre-Bénite, France, 69310 收起 <<
NCT02272998	Malignant Neoplasm	Phase 2	Recruiting	December 31, 2017	United States, Michigan ... 展开 >> University of Michigan Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Ajjai Alva, MD 734-936-8906 Ajjai@med.umich.edu Principal Investigator: Ajjai Alva United States, Ohio Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center Recruiting Columbus, Ohio, United States, 43210 Contact: Sameek Roychowdhury, MD 614-685-5842 Sameek.Roychowdhury@osumc.edu Principal Investigator: Sameek Roychowdhury, MD 收起 <<
NCT03171389	GIST, Malignant ... 展开 >> KIT Exon 13 Mutation KIT Gene Mutation 收起 <<	Phase 2	Recruiting	September 22, 2020	Germany ... 展开 >> West German Cancer Center Recruiting Essen, NRW, Germany, 45122 Principal Investigator: Sebastian Bauer, Prof. Dr. 收起 <<
NCT03709017	-		Recruiting	December 2023	Korea, Republic of ... 展开 >> Kosin University Gaspel Hospital Recruiting Busan, Korea, Republic of Contact: Hosup Lee 收起 <<
NCT02398825	Chronic Myeloid Leukemia ... 展开 >> Chronic Phase Adults 收起 <<	Phase 2	Recruiting	December 2020	Italy ... 展开 >> Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi Recruiting Ancona, Italy Contact: Serena Rupoli Principal Investigator: Serena Rupoli Azienda Ospedaliera Di Bologna Policlinico S. Orsola - Malpighi Recruiting Bologna, Italy, 40138 Contact: Gianantonio Rosti, Dr. Principal Investigator: Gianantonio Rosti, Dr. Università di Catania - Cattedra di Ematologia - Ospedale "Ferrarotto" Recruiting Catania, Italy Contact: Fabio Stagno Principal Investigator: Fabio Stagno Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia- Padiglione Marcora 2° piano Recruiting Milano, Italy Contact: Alessandro Iurlo Principal Investigator: Alessandro Iurlo Milano Unità Trapianto di Midollo Ist. Nazionale Tumori Recruiting Milano, Italy Contact: Francesco Spina Principal Investigator: Francesco Spina Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale G. da Saliceto Recruiting Piacenza, Italy Contact: Daniele Vallisa Principal Investigator: Daniele Vallisa 收起 <<
NCT02829840	Leukemia FLT3... 展开 >>-Mutated Acute Myeloid Leukemia FLT3-Mutated High-Risk Myelodysplastic Syndrome 收起 <<	Phase 1 Phase 2	Withdrawn	-	-
NCT01667133	Chronic Myeloid Leukemia (CML)... 展开 >> Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 收起 <<	Phase 1 Phase 2	Completed	-	Japan ... 展开 >> Aichi Cancer Center Hospital Nagoya-shi, Aichi, Japan, 464-8681 Akita University Hospital Akita-shi, Akita, Japan, 010-8543 Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital Hiroshima-shi, Hiroshima, Japan, 730-8619 Kyushu University Hospital Hukuoka-shi, Hukuoka, Japan Kinki University Hospital, Faculty of Medicine Osakasayama-shi, Osaka, Japan, 589-8511 The Cancer Institute Hospital Japanese Foundation for Cancer Research Koto, Tokyo, Japan The University of Tokyo, The Institute of Medical Science Minato-ku, Tokyo, Japan Keio University Hospital Shinjuku-ku, Tokyo, Japan Osaka City University Hospital Shinjuku-ku, Tokyo, Japan National Cancer Center Hospital Chuo-ku, Tokyo, Japan Tokyo Medical University Hospital Shinjuku-ku, Tokyo, Japan 收起 <<
NCT01874665	GIST	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital, Site #047 Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute, Site #008 Boston, Massachusetts, United States, 02215 United States, Oregon Oregon Health & Sciences University, Site #048 Portland, Oregon, United States, 97239 United States, Pennsylvania Fox Chase Cancer Center, Site #012 Philadelphia, Pennsylvania, United States, 19111 收起 <<
NCT01874665	-		Completed	-	-
NCT02478164	Glioblastoma	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT02478164	-		Completed	-	-
NCT03690115	Leukemia, Myeloid, Acute	Phase 2	Not yet recruiting	May 2022	France ... 展开 >> CHU NAgers Not yet recruiting Angers, France Contact: François CHu Brest Not yet recruiting Brest, France Contact: Guillerm CHU Caen Not yet recruiting Caen, France Contact: Chantepie CHU Clermont Ferrand Not yet recruiting Clermont Ferrand, France Contact: Guieze CHU Grenoble Not yet recruiting Grenoble, France Contact: Bulabois CHU Lille Not yet recruiting Lille, France Contact: Yakoub Agha CHU Limoges Not yet recruiting Limoges, France Contact: Turlure Chevallier Not yet recruiting Nantes, France Contact: Patrice Chevallier Hopital St Antoine Not yet recruiting Paris, France Contact: Mothy Hopital St Louis Not yet recruiting Paris, France Contact: Regis Peffault de la tour CHu Lyon Not yet recruiting Pierre-Bénite, France Contact: Labussière CHU Poitiers Not yet recruiting Poitiers, France Contact: Maillard CRLC Toulouse Not yet recruiting Toulouse, France Contact: Huynh CHU Nancy Not yet recruiting Vandœuvre-lès-Nancy, France Contact: Rubio 收起 <<
NCT01592136	-		-	-	-
NCT02627677	Chronic Phase Chronic Myeloid ... 展开 >>Leukemia 收起 <<	Phase 3	Active, not recruiting	December 31, 2022	Belgium ... 展开 >> Cliniques Universitaire Saint-Luc (Site 058) Bruxelles, Belgium, 1200 收起 <<
NCT01813734	Non Small Cell Lung Cancer	Phase 2	Completed	-	United States, California ... 展开 >> University of California, Irvine Orange, California, United States, 92868 United States, Maryland University of Maryland Baltimore, Maryland, United States United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02115 United States, Michigan Karmanos Cancer Institute Detroit, Michigan, United States United States, Ohio Ohio State University Columbus, Ohio, United States, 43210 收起 <<
NCT01570868	Leukemia	Phase 2	Terminated(Closed due to slow ... 展开 >>accrual) 收起 <<	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01935336	Adenocarcinoma of the Lung ... 展开 >> Extensive Stage Small Cell Lung Cancer Limited Stage Small Cell Lung Cancer Recurrent Non-small Cell Lung Cancer Recurrent Small Cell Lung Cancer Stage IIIA Non-small Cell Lung Cancer Stage IIIB Non-small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer 收起 <<	Phase 2	Active, not recruiting	December 2020	United States, Colorado ... 展开 >> University of Colorado Cancer Center Aurora, Colorado, United States, 80045 收起 <<
NCT01761747	-		Terminated(FDA hold and toxici... 展开 >>ty associated with study drug) 收起 <<	-	-
NCT01888562	Endometrial Neoplasms	Not Applicable	Withdrawn(Could not obtain an ... 展开 >>IDE on the FGFR2 assay) 收起 <<	July 2023	-
NCT02428543	Acute Myeloid Lukemia	Phase 1 Phase 2	Recruiting	September 2020	France ... 展开 >> Dr Abdelaziz CHAIB Recruiting Aix-en-Provence, France, 13600 Contact: Abdelaziz CHAIB achaib@ch-aix.fr Principal Investigator: Abdelaziz CHAIB Chu Amiens Recruiting Amiens, France, 80054 Contact: MAROLLEAU Jean Pierre Principal Investigator: MAROLLEAU Jean Pierre CHU d'Angers Recruiting Angers, France, 49033 Contact: Martine GARDEMBAS Magardembas@chu-angers.fr Principal Investigator: Martine GARDEMBAS Hôpital VICTOR DUPOUY Recruiting Argenteuil, France, 95107 Contact: AL JIJAKLI Ahmad ahmad.aljijakli@ch-argenteuil.fr Principal Investigator: AL JIJAKLI Ahmad Dr Edouard RANDIAMALALA Recruiting Bayonne, France, 64100 Contact: Edouard RANDIAMALALA erandiamalala@ch-cotebasque.fr Principal Investigator: Edouard RANDIAMALALA CHU de Besançon Recruiting Besançon, France, 25030 Contact: Fabrice LAROSA flarosa@chu-besançon.fr Principal Investigator: Fabrice LAROSA Dr Thorsten BRAUN Recruiting Bobigny, France, 93000 Contact: Thorsten BRAUN thorsten.braun@aphp.fr Principal Investigator: Thorsten BRAUN CHU Boulogne Sur Mer Recruiting Boulogne Sur Mer cedex, France, 62321 Contact: CHOUFI Bachra b.choufi@ch-boulogne.fr Principal Investigator: CHOUFI Bachra Chr Clemenceau Recruiting Caen Cedex, France, 14033 Contact: REMAN Oumédaly reman-o@chu-caen.fr Principal Investigator: REMAN Oumédaly Hôpital d'Instruction des Armées PERCY Recruiting Clamart, France, 92141 Contact: Jean Valère MALFUSSON jvmalf@free.fr Principal Investigator: Jean Valère MALFUSSON Dr Stéphanie HAÏAT Recruiting Corbeil-essonnes, France, 91100 Contact: Stéphanie HAÏAT Principal Investigator: Stéphanie HAÏAT Hôpital Henri Mondor Recruiting Créteil, France, 94010 Contact: PAUTAS Cécile cecile.pautas@hmn.aphp.fr Principal Investigator: PAUTAS Cécile CHU de Dijon Not yet recruiting Dijon, France, 21079 Contact: CAILLOT Denis denis.caillot@chu-dijon.fr Principal Investigator: CAILLOT Denis Centre hospitalier de Versailles Recruiting Le Chesnay cedex, France, 78157 Contact: Rousselot Philippe 003339638622 phrousselot@ch-versailles.fr Principal Investigator: Rousselot Philippe Hôpital Claude Huriez Recruiting Lille cedex, France, 59037 Contact: QUESNEL Bruno bquesnel@chru-lille.fr Principal Investigator: QUESNEL Bruno CHRU Dupuytren Not yet recruiting Limoges cedex, France, 87042 Contact: TURLURE Pascal pascal.turlure@chu-limoges.fr Principal Investigator: TURLURE Pascal Hôpital Edouard Herriot Recruiting Lyon cedex 03, France, 69437 Contact: THOMAS Xavier xavier.thomas@chu-lyon.fr Principal Investigator: THOMAS Xavier Dr Regis COSTELLO Recruiting Marseille, France, 13000 Contact: Regis COSTELLO regis.costello@ap-hm.fr Principal Investigator: Regis COSTELLO Centre Hospitalier de Meaux Recruiting Meaux, France, 77104 Contact: FRAYFER Jamilé j-frayfer@ch-meaux.fr Principal Investigator: FRAYFER Jamilé Dr Mario OJEDA-URIBE Recruiting Mulhouse, France, 68000 Contact: Mario OJEDA-URIBE ojedam@ch-mulhouse.fr Principal Investigator: Mario OJEDA-URIBE Dr Jacques DELAUNAY Recruiting Nantes, France, 44000 Contact: Jacques DELAUNAY jacques.delaunay@chu-nantes.fr Principal Investigator: Jacques DELAUNAY CHU Nice, Hôpital Archet 1 Recruiting Nice cedex 3, France, 06202 Contact: MANNONE Lionel mannone.l@chu-nice.fr Principal Investigator: MANNONE Lionel CHU de Nîmes Recruiting Nîmes, France, 30029 Contact: Eric JOURDAN eric.jourdan@chu-nimes.fr Principal Investigator: Eric Jourdan Hôpital Saint Antoine Recruiting Paris cedex 12, France, 75751 Contact: ISNARD Françoise francoise.isnard@sat.aphp.fr Principal Investigator: ISNARD Françoise Hôpital Necker Enfants Malades Recruiting Paris cedex 15, France, 75743 Contact: SUAREZ Felipe felipe.suarez@nck.aphp.fr Principal Investigator: SUAREZ Felipe Hôpital Saint Louis Recruiting Paris, France, 75010 Contact: RAFFOUX Emmanuel emmanuel.raffoux@sls.ap-hop-paris.fr Principal Investigator: RAFFOUX Emmanuel Hôpital La Pitié Salpêtrière Recruiting Paris, France, 75013 Contact: UZUNOV Madalina madalina.uzunov@psl.aphp.fr Principal Investigator: UZUNOV Madalina Dr Laurence SANHES Suspended Perpignan, France, 66000 Dr Arnaud PIGNEUX Recruiting Pessac, France, 33604 Contact: Arnaud PIGNEUX arnaud.pigneux@chu-bordeaux.fr Principal Investigator: Arnaud PIGNEUX Centre Hospitalier René Dubos Recruiting Pontoise Cedex, France, 95303 Contact: VAIDA Iona Dana ioana.vaida@ch-pontoise.fr Principal Investigator: VAIDA Iona Dana Marc BERNARD Recruiting Rennes, France, 35000 Contact: Marc BERNARD marc.bernard@chu-rennes.fr Principal Investigator: Marc BERNARD Dr Emilie LEMASLE Recruiting Rouen, France, 76000 Contact: Emilie LEMASLE emilie.lemasle@chb.unicancer.fr Principal Investigator: Emilie LEMASLE Centre Hospitalier René Huguenin Suspended Saint Cloud, France, 92210 Institut de Cancérologie de la Loire Recruiting Saint-Priest-en-Jarez, France, 42270 Contact: Emmanuelle TAVERNIER-TARDY emmanuelle.tavernier@icloire.fr Principal Investigator: Emmanuelle TAVERNIER-TARDY Dr Réda GARIDI Recruiting Saint-Quentin, France, 02100 Contact: Réda GARIDI Principal Investigator: Réda GARIDI Dr Christian RECHER Recruiting Toulouse, France, 31000 Contact: Christian RECHER Principal Investigator: Christian RECHER Centre Hospitalier de Valenciennes Recruiting Valenciennes, France, 59322 Contact: FERNANDES José fernandes-j@ch-valenciennes.fr Principal Investigator: FERNANDES José 收起 <<
NCT01761747	Non-Small Cell Lung Cancer, He... 展开 >>ad and Neck Cancer 收起 <<	Phase 2 Phase 3	Terminated(FDA hold and toxici... 展开 >>ty associated with study drug) 收起 <<	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02214 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Brigham and Women's Hospital Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<

普纳替尼 /Ponatinib {[allProObj[0].p_purity_real_show]}

Ponatinib 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Ponatinib 质控信息

Ponatinib 生物活性

Ponatinib 细胞研究

Ponatinib 动物研究

Ponatinib 临床研究

Ponatinib 实验方案

Ponatinib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

普纳替尼 /Ponatinib {[allProObj[0].p_purity_real_show]}

Ponatinib 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Ponatinib 质控信息

Ponatinib 生物活性

Ponatinib 细胞研究

Ponatinib 动物研究

Ponatinib 临床研究

Ponatinib 实验方案

Ponatinib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Ponatinib 纯度/质量文件产品仅供科研